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Malaria is one of the leading causes of death worldwide, particularly amongst 
developing countries. One of the most severe complications of Plasmodium 
falciparum infection which accounts for more than 80% of malaria-related deaths in 
children less than five-years-old, is a neuropathology known as human cerebral 
malaria (HCM). This neurological complication results in severe dysfunction in CNS 
such as abnormal posturing, seizures and coma. However, due to moral issues, 
limited knowledge has been derived on the disease progression. As such, mouse 
model is heavily relied on to study the pathogenesis of HCM.  
 
Results from experimental cerebral malaria (ECM) have identified this 
neuropathology as a result of an overwhelming host immune response during 
infection. Pro-inflammatory response is initiated through recognition of malarial 
products, which could go through several downstream signalling pathways and 
eventually activate transcription factors, such as NF-κB, AP-1 and interferon 
regulatory factors (IRFs). Each IRF mediates transcription of different sets of 
cytokine and proteins which further control the immune response. During PbA 
infection, upregulated expression of genes in the IRF family has been observed. 
Therefore, in this project, we study the contribution of IRF in ECM development.    
 
We focused on three different transcription factors, IRF3, IRF7 and IRF1. IRF3 and 
IRF7 are master regulator of IFN-I. Using mice deficient of receptor of IFN-I, it has 
been shown that IFN-I is crucial to ECM progression. On the other hand, IRF1 
regulates production of IFN-I and IFN-II. Previous studies demonstrated that absence 
of IRF1 conferred protection against ECM in mice. In our project, using mice 
deficient of each IRF, we revealed that IRF1 and IRF3 are both crucial but each 
participates differently in the development of ECM. IRF7, though not essential for 
xviii 
 
ECM, is involved in the control of peripheral parasitemia by regulating the IFN-γ-
producing CD4+ T cells. During infection, absence of IRF1 alters IFN-γ/IL-10 ratio 
and therefore skews the inflammatory response away from the pathogenic Th1 
response. On the other hand, IRF3 controls IFN-β and IFN-γ production which 
mediates antigen cross-presentation by brain endothelial cells. By putting the data 
together, we concluded that antigen cross-presentation is the most important event 
that determines ECM susceptibility and this can be regulate by both IFN-γ and IFN-β.   
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CHAPTER 1 INTRODUCTION 
1.1 Overview of Malaria Infection 
Malaria is an infectious disease that has plagued mankind for decades. Today, malaria 
remains an on-going transmitted disease in 97 countries mainly in Asia, Africa and 
Sub-Sahara Africa and Latin America. It is ranked as one of the top three infectious 
disease killers, together with human immunodeficiency virus (HIV)/acquired 
immunodeficiency syndrome (AIDS) and tuberculosis (TB). According to WHO 
Malaria Report 2014, an estimated 198 million clinical cases and approximately 
600,000 malaria-related deaths were reported in 2013. Notably, more than half of the 
deaths occurred amongst African children younger than five-years-old, with an 
average of a child dying of malaria every 30 seconds [1]. Out of which, human 
cerebral malaria (HCM) accounts for 12% fatality in this population [2, 3]. Although 
this form of severe malaria bears only a modest proportion of total malaria cases, the 
number of HCM cases still amount to a staggering figure each year. On top of this, 
this neuropathology has high fatality rate [4, 5]. Taken together, it is of great 
importance to understand the underlying mechanism and thereby, possibly, propose 
possible therapeutic interventions.  
 
1.2 Life Cycle of Malaria Parasite 
The malaria parasite is a unicellular protozoan of the Plasmodium genus, with over 
200 species of parasite that infects birds, reptiles and mammals. In human, there are 
six parasite species, namely P. falciparum, P. vivax, P.ovale, P.malariae, 
P.cynomolgi and P.knowlesi [6], the last two being zoonosis.  
 
The life cycle of Plasmodium alternates between two distinct phases: sexual stage in 
female Anopheles mosquito and asexual stage in human host (Figure 1.1). When an 
infected female Anopheles mosquito feeds on human (1), it simultaneously inoculates 
sporozoite in its saliva into the host’s dermis (2). Up to 200 sporozoites can be 
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transmitted per mosquito bite. These motile sporozoites leave the skin and travel 
through the circulation, eventually settling in the hepatocytes (3). It is assumed that 
this whole process of migration and invasion occurs within 30mins of inoculation.  
 
During the liver phase, sporozoite in each hepatocyte undergoes several asexual 
multiplications to produce thousands of haploid forms, called merozoites. This stage 
of exoerythrocytic schizogony takes about two to twenty-one days with each schizont 
containing an average of 30,000 merozoites. Eventually, vesicles containing matured 
infective merozoites, called merosomes, are released from the hepatocytes into the 
peripheral blood circulation [7]. This marks the end of the clinically silent exo-
erythrocytic stage of the life cycle. 
 
Merosomes circulating within the bloodstream accumulate and rupture in the 
pulmonary microcirculation, releasing the merozoites which immediately infect red 
blood cells (RBC) (3) [8]. Invasion is initiated through weak interactions between 
surface proteins on the merozoites and receptors on target RBCs. As the parasite 
move into the target cells, it sheds off most of these surface proteins and differentiates 
into a ring trophozoite.  
 
Parasite relies on the haemoglobin within infected red blood cells (iRBC) as a major 
source of amino acid for growth [9-11]. It possesses machinery that detoxifies the 
haemoglobin heme into a nontoxic product, Hemozoin, a metabolic by-product which 
is kept in its digestive vacuole [12, 13]. Through series of asexual multiplication, the 
merozoite matures from a ring form, into trophozoite, and finally into a schizont (4), 
containing up to 36 daughter merozoites, differing between each parasite species [14]. 
Ultimately, the schizont will burst to release these merozoites into the circulation, 
which will move on to infect new RBC within seconds, and kick start another round 
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of erythrocytic cycle. Rupture of schizont in each cycle accounts for the classic 
periodic fever observed amongst malaria patients.  
 
While most merozoites re-enter the erythrocytic cycle of infection, multiplication and 
egression, some merozoites leave this cycle to form sexual forms termed gametocytes 
(6). These parasite forms remain in the infected red blood cells (iRBC) until they are 
ingested by a feeding mosquito where it matures into uninucleated sporozoites, ready 
for its next infection [15].  
 
 
Figure 1.1 Life cycle of malaria parasite in human 
When an infected mosquito is taking a blood meal (1), it injects sporozoite contained 
in the saliva into the dermis of the victim (2). These motile parasite forms travel into 
circulation and settle in the liver where they infect the hepatocytes (3). After a series 
of asexual multiplication within the hepatocyte, the parasite is once again released 
into the circulation in the form of merozoite. These merozoites infect circulating RBC 
(4). Within the RBC, the parasite matures from a ring form, trophozoite, to a late 
trophozoite and finally into a schizont (5). Rupture of schizont releases numerous 
merozoites into the circulation which re-enters RBC to kick start another round of 
erythrocytic cycle. Some merozoites leave this cycle to form gametocytes and are 
ingested by the next feeding mosquito (6). (Adapted from Hill et al., [16]) 
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1.3 Clinical Manifestation  
1.3.1 Signs and Symptoms 
The asexual erythrocytic stage of the life cycle is responsible for the clinical 
manifestations of malaria infection. Schizont rupture releases merozoites and other 
parasite products into the circulation thereby triggering the host immune response, 
leading to the paroxysms of fever and chills. The time from initial exposure to 
symptoms appearance typically ranges from seven to forty days, depending on the 
parasite species [17-19].  
 
All six species of parasite induce the classical clinical features of alternate fever, 
shaking chills and diaphoresis [20]. Malarial paroxysm exhibits varying periodicity. 
For P.knowlesi, the febrile attacks appear every 24h; for P.vivax, P.ovale, and 
P.cynomolgi, episodes of fever and chills occurs every 48h; for P.malariae, the 
recurring fever develops every 72h. P.falciparum does not exhibit distinct paroxysms 
but could manifest as a continuous fever, daily or irregular attacks. Other common 
symptoms of malaria include fatigue, dizziness, body ache, diarrhea, nausea and 
vomiting [21].  
 
Prompt treatment with anti-malarial drugs such as quinine, chloroquine, artesunate 
and sulfadoxine-pyrimethamine are used to achieve full recovery in patients with 
uncomplicated malaria. However, recent emergence of drug-resistance parasites, in 
particular among the species of Pf, has affected the efficacy of monotherapy and 
required combinational treatment such as the artesunate combined therapy (ACT). 
The situation is bleaker since Pf induces the most serious clinical forms of malaria 
infection. As such, Pf-infected patients are at higher risk of progressing to 
complicated severe malaria.   
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1.3.2 Severe Malaria 
Pf is the most deadly specie and accounts for the highest fatality rate in malaria due to 
its ability to sequester in major organs that could develop into multi-organ failure or 
severe malaria [22]. Severe Pf malaria can manifest in many forms and Table 1.1 
charted the list and criteria as defined by WHO [23]. Among the complications of 
severe malaria, HCM is the most lethal form.  
 
Table 1.1 Definition of severe Pf malaria [23-25] 
Severe anaemia Haemoglobin <50 g/L or haematocrit < 15% with parasite 
count > 10,000/ul 
Hyperparasitemia Parasitemia > 5% or > 250,000 parasites/ul 
Hyperbilirubinemia Total bilirubin > 43 µmol/L (> 2.5mg/dl) 
Hypoglycaemia Whole blood glucose < 2.2 mmol/L (40mg/dl) 
Hyperpyrexia Core body temperature > 40
o
C 
Coagulation failure Spontaneous bleeding from many sites in the body and/or 
laboratory evidence of disseminated intravascular coagulation 
(DIC)   
Circulatory collapse 
(Shock) 




Renal failure Low urine output of < 400ml/24h (< 12ml/kg/24h in children) 
with high level of serum creatinine > 265 µmol/L  
Respiratory distress Pulmonary oedema or acute respiratory distress with injury 
score calculated based on radiographic densities, severity of 
hypoxemia and positive end-expiratory pressure  
Cerebral malaria Altered consciousness (Glasgow Coma Scale score ≤ 9) not 
attributed to other causes of encephalopathy 
Unarousable coma occurs before or after onset of convulsion 
 
1.4 Human Cerebral Malaria  
1.4.1 Impact of Cerebral Malaria 
Human cerebral malaria (HCM) is the most life-threatening complication of severe 
malaria and accounts for the highest fatality recorded in malaria infection. This 
debilitating encephalopathy mainly affects individual who has yet to develop 
acquired immunity against malaria, primarily children under 5 years old living in 
endemic areas [26]. Adults, such as pregnant women and travellers with no prior 
exposure to infection, are also vulnerable to HCM. This neuropathology may occur 
within two weeks of infection or after two to seven days of fever [23]. Patients 
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suffering from HCM can display neurological symptoms such as seizures, abnormal 
motor posturing, confusion, stupor and even deep coma [27, 28]. Lack of treatment is 
invariably fatal, and even under optimal treatment conditions, case fatalities remain 
high at 15-20% [29, 30]. In some cases, survivors of HCM could transiently or 
permanently suffer from a spectrum of neurological sequelae ranging from loss of 
motor function, such as coordination and speech, to cognitive impairment and even 
epilepsy [31, 32]. As such, the impact of this neuropathology has a far-reaching social 
and economic burden.  
 
1.4.2 Brain Pathology – Blood-Brain Barrier 
Abnormal neurological manifestation in HCM is an indicator of damage to the central 
nervous system (CNS) due to a breach in the blood-brain barrier (BBB). This highly 
specialized interface between the intravascular space and CNS normally regulates 
permeability and molecular movement into the brain parenchyma thereby providing a 
stable environment for proper neural function. The structural components that 
maintain such important function are the endothelial cells, basement membrane and 
perivascular cells such as astrocytes and microglia. Specially adapted endothelial 
cells attached by complex tight junction proteins such as occludin, vinculin and zona 
occludens (ZO) form the basis of BBB. Therefore, selective loss of these tight 
junctional proteins leading to changes in BBB permeability will result in the loss of 
barrier properties. Alterations in BBB permeability in HCM patients can be assessed 
by measuring the presence of albumin and immunoglobulin in the cerebrospinal fluid 
(CSF), which are normally excluded from the brain. No significant increase in 
albumin level within CSF was found in Vietnamese HCM cases as compared to 
control subjects [33]. Similarly, no increase in albumin level was observed in Thai 
adults during and after coma induced by HCM [34]. In Malawian children, the level 
of albumin was also not different between fatal and surviving cases, although some 
difference was observed when compared to UK adult controls [35]. On the other hand, 
 Chapter 1 Introduction   
8 
 
higher IgG level was detected in the CSF of significant number of Thai patients 
suffering from HCM [36]. Such discrepancies could be dependent on the specific 
time point when samples are obtained. Altogether, these suggest absence of major 
injury to the BBB and only presence of minute ruptures that may result from 
endothelial cell activation. Through immunohistochemistry staining of post-mortem 
brain samples, considerable loss of such tight junction proteins occludin, vinculin and 
ZO-1 was observed in HCM cases as compared to non-HCM and uninfected control 
samples. Another indication of compromised BBB in HCM patients is the significant 
increase in the level of scavenger receptor and sialoadhesin in perivascular 
macrophages as compared to non-HCM and control samples, indicating activation of 
perivascular macrophages in response to abnormal leakage of plasma proteins across 
the cerebral endothelium [37, 38].  
 
1.4.3 Proposed Hypotheses to HCM Pathogenesis 
Two main hypotheses were put forward to explain for the damage in BBB based on 
histopathological observations, which are the sequestration theory and the 
immunological theory. The sequestration theory originated from the widespread 
observations of microvascular blockage by iRBC in post-mortem samples of HCM 
patients in several independent but limited studies [39-43]. While these reports 
associated sequestered iRBC “plugging” the microvasculature with development of 
neurological syndrome, such histopathological features were nearly absent in some 
other human studies suggesting possibilities of other factors playing a more important 
role in HCM pathogenesis [44-46]. The immunological theory, defined by an over-
vigorous immune response, was proposed after observations that malnourished 
African children with a depressed cell-mediated immunity were less prone to HCM 
[47].  
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Sequestration of iRBC in the brain microvasculature was first highlighted by Laveran 
in 1893, when he observed singular bodies of the black pigment granulations in the 
cerebral vessels of subjects that died of pernicious malaria [48]. Subsequently, 
Marchiafava and Bignami came up with the idea that RBC loaded with amoeba-like 
bodies that ‘plug’ the brain vessels causes mechanical obstruction to the 
microcirculation, disrupts blood flow, decreases supply of nutrients to the brain, 
thereby inducing pathological changes in the brain [49, 50]. And indeed 
histopathological study that followed identified positive correlation in iRBC 
sequestration in the brain with disease severity in HCM patients [51]. IRBC 
sequestration was observed in many organs but mostly found the brain of HCM 
patients. Ultrastructural analysis revealed that late-stage parasite like trophozoites and 
schizonts are mainly involved in sequestration which otherwise do not follow any 
pattern and is random and uneven [39, 51-54]. Detailed examination of these 
sequestered iRBC under electron microscope revealed dense protruding knobs on the 
membrane of the iRBC that form junctions with the brain endothelial cells [39, 42, 
53]. These protruding knobs present parasite molecules, such as Pf erythrocyte 
membrane protein 1 (PfEMP1) [42], which account for the adhesive properties of 
sequestered iRBC [55]. Interacting with these parasite adhesins are cytoadherence 
receptors expressed on the cerebrovascular endothelial cells [53]. Some putative 
endothelial receptors are CD31, CD36, ICAM-1, VCAM-1, EPCR, E-selectin, P-
selectin and chondroitin sulphate A [56-64]. 
 
Presence of leukocytes and platelets sequestration in the brain tissue of some 
Malawian children [65, 66] and India [67] patients suggested that iRBC sequestration 
is not uniquely responsible for HCM pathogenesis and host immune response can 
participate in the disease development. Immunological theory encompassed several 
different elements in the immune system. Some popular players include circulating 
immune complexes (CIC) [68], complements [68-70], platelets, pro-inflammatory 
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cytokines [71, 72] and cellular immune responses [73]. Out of which, the theory of 
overwhelming cytokine response garnered most support as numerous post-mortem 
and serological studies suggest its involvement in HCM pathogenesis. The cytokine 
theory was first proposed by Clark and Rockett who argued that HCM occur 
independently of significant sequestration. They proposed that cytokines, such as 
tumour necrosis factor-alpha (TNF-ɑ), play a more central role in the development of 
this neuropathology [72]. Kern et al., supported this notion when he demonstrated a 
positive correlation between biologically detectable level TNF-ɑ and interleukin 6 
(IL-6) with disease severity in complicated malaria [74]. Amongst Malawian children, 
increasing serum TNF-ɑ was associated with mortality [75]. Similarly, higher plasma 
TNF-ɑ was detected in Gambian children suffering from HCM than those with 
uncomplicated malaria [76]. On the other hand, IFN-gamma (IFN-γ) was detected in 
the serum of all HCM patients in Thailand, often preceded by presence of serum IFN-
alpha (IFN-ɑ) [77]. Through in vitro stimulation of malaria-naïve donors with either 
Pf iRBC or plasmodium supernatant, it was demonstrated that early Pf iRBC-induced 
TNF response was associated with IFN-γ production and critically dependent on 
macrophage-lymphocyte interactions [78-80]. Another form of TNF is TNF-β (also 
known as Lymphotoxin-alpha) which shares the same apoptotic function and receptor 
as TNF-ɑ (TNFR2). Elevating level of TNF-β in malaria patients [81], along with its 
production by human mononuclear leukocytes when stimulated with lysates of Pf 
[82], suggest possible involvement of this cytokine in malaria infection and HCM, 
although further systematic study is required to confirm their role in HCM. Another 
cytokine implicated in HCM is Interleuin-1 beta (IL-1β) which is a neurotoxin and 
normally not expressed in the brain. Post-mortem tissue samples collected from the 
brain of Malawian children suffering from HCM expressed this cytokine [38]. 
However, this upregulated expression of IL-1β was not specific to HCM [38] and no 
significant difference was detected when compared to patients with uncomplicated 
malaria [83]. Taken together with margination of leukocytes to the vascular 
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endothelium  in HCM brain tissue samples [67] [66, 84], it seems plausible that 
immune cells producing pro-inflammatory cytokines (TNF-ɑ, IFN-γ, TNF-β, IL-1β) 
are involved in the pathogenesis. Unlike the extensive data available supporting the 
sequestration theory, limited access to brain tissues at crucial time-points upon the 
onset of HCM led to relative restricted data available on the role of immune cells and 
pro-inflammatory cytokines in HCM so their roles are not clearly established.   
 
1.5 Experimental Cerebral Malaria  
1.5.1 Rationale for Models of ECM  
Histopathological examinations of post-mortem brain sample enabled observations of 
changes upon HCM deaths while serological studies establish correlation patterns. 
Yet, there are often discrepancies in conclusion due to heterogeneous results possibly 
confounded by varied time of death, treatments administered, other medical 
complications and genetic backgrounds. Moreover, samples are hard to come by and 
they do not permit study to address differences between survivors and victims. Most 
importantly, autopsy studies merely entails studies of association but are unable to 
draw conclusion on causality thereby posing great difficulty in delineating the 
sequences of pathogenic processes that causes HCM symptoms. Although non-
invasive imaging techniques, such as computational topography and magnetic 
resonance imaging, are available to resolve such limitations [85-87], these procedures 
are often expensive to perform and severely restricted by ethical constraints for 
further mechanistic studies. Therefore, in order to move on from purely descriptive 
and correlative studies, it is clear that experimental animal model should be employed 
to fully understand HCM pathogenesis.      
 
1.5.2 Models of ECM 
Non-human primates (NHP) cerebral malaria model, for example rhesus monkeys 
infected with P.coatneyi, P.fragile or P.knowlesi [88-91] and squirrel monkeys 
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infected with Pf [92], exhibits clinical symptoms and characteristic brain pathology of 
HCM, such as vascular plugging by iRBC [93-95], increased expression of ICAM-1, 
CD36 and thrombospondin [95] as well as upregulated level of pro-inflammatory 
cytokines like TNF and IFNγ [96]. Given the great genetic relevance of NHP and 
primate parasite to their human counterparts, the NHP model of cerebral malaria with 
its close clinical features is the most ideal animal model. However due to ethical and 
cost issues, only a small number of NHP are permitted for each study rendering it an 
undesirable model for basic mechanistic studies. Hence, there is a need for alternative 
animal models.  
 
Despite all controversies, murine experimental cerebral malaria (ECM) model 
remains an indispensable tool to understand the patho-physiological mechanism of 
HCM. In addition, defined genetic background of mice is readily available, and most 
importantly, the ever-expanding collection of transgenic or gene-deficient mice 
enables a variety of mechanistic studies to be performed. Although there is a lot of 
misconception and lack of proper understanding of this model by scientist working in 
HCM, it is undisputable that the mouse model has provided important data and basic 
knowledge relevant to the understanding of the human disease. In malaria, there are 
four rodent species, namely P.chabaudi, P.vinckei, P.yoelii, and P.berghei, thirteen 
subspecies, numerous strains and clones. The ANKA strain of P.berghei (PbA) is the 
most commonly used parasite in laboratories since the genome has been fully 
sequenced [97] and transfection system was first established in this strain [98]. Table 
1.2 summarizes the different combinations of mouse strains and PbA clones used to 
study the mechanism leading to ECM susceptibility or resistance. Susceptible mice 
infected with PbA replicates many features and events observed in HCM. Infection 
induces neuropathological symptoms such as ataxia, paralysis and coma within a 
week. This is typically ensued with death in the next 24h after apparent clinical signs. 
Usually, 60 to 100 percent of the infected mice succumbed to ECM during 6 to 14 
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days of post-infection. Remaining mice that were protected from ECM will die of 
hyperparasitemia and anaemia at the end of two weeks. Time frame of disease 
occurrence and incidence of ECM varies depending on mouse genetic background 
[99], parasite form (sporozoite vs. fresh iRBC vs. frozen iRBC) [100], parasite clones, 
dosage and passage in different moue strains [99].  
 
Table 1.2 Combination of different mouse strains and PbA clones to study the 
mechanism leading to ECM susceptibility and resistance 





129/Ola x C57BL/6 
129P2Sv/Ev 
129 Sv/Ev x 
C57BL/6 
 




P.berghei ANKA-luc (231c11)  [117, 
118] 
P.berghei ANKA-GFP  [119, 
120] 
P.berghei ANKA clone 15cy1 [121, 
122] 
P.berghei ANKA-GFP clone 
15cy1 
[123]  
P.berghei ANKA clone BdS [124, 
125]  
P.berghei ANKA sporozoite [101] 
P.berghei ANKA clone 15cy1 
sporozoite 
[122] 
CBA/J P.berghei ANKA [111] 
CBA/T6 P. berghei ANKA [126] 





P.berghei K173 [106] 
CBA/T6 P.berghei K173 [126] 




P.berghei ANKA clone BdS [124] 
P.berghei ANKA-GFP [119] 
 
The murine ECM model recapitulates neurological symptoms observed in HCM as 
well as histopathological features in the brain, such as haemorrhages and BBB 
alterations. However, due to differences in parasite biology, the murine model still 
displays some disparity when compared to the human disease. Histopathological 
examination of brain samples from mice with ECM displayed accumulation of 
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leukocytes and, to a less extent, iRBC [128] which clearly contrasted with the widely 
observed iRBC sequestration in HCM samples. Although it has raised concerns on its 
applicability to the study of HCM, several reviews [129, 130] have established that 
this observations cannot be taken alone, as other factors are likely to be involved in 
the pathogenesis [131, 132]. In addition, iRBC sequestration, albeit at a much lower 
level, has been documented in various ECM models [133-135] and compared to mice 
that are resistant to ECM (NCM), ECM-susceptible mice had significantly higher 
parasite sequestered in the brain [117]. More importantly, parasite burden in the brain 
can vary widely with some HCM patients with minimal or no iRBC sequestration 
suggesting that there could be other possible pathogenic pathway leading to this 
encephalitis [46, 134]. While the pathogenic role of T cells, particularly CD8+ T cells, 
has clearly been demonstrated in ECM, lack or rarity of T cells in post-mortem 
histology HCM samples once again cast doubts on the findings from animal model. 
However, it is possible that basic histology is not sensitive enough to detect 
sequestered leukocytes in the HCM samples since the numbers are not large even in 
the brain of ECM-afflicted mice (50,000 CD8+ T cells in 400mm
3
 brain volume) 
[136]. Therefore, findings from murine ECM studies should not be discredited but 
rather taken into considerations when applied to studies in HCM.   
 
1.5.3 Pathogenesis in the Brain 
Kinetic analysis demonstrated that leukocyte recruitment occurs concurrently with the 
manifestation of neurological signs [124], which highlights the importance of 
leukocytes in ECM pathogenesis. Sequestered leukocytes in the brain are composed 
of  monocytes, neutrophils, platelets, NK cells, CD4+ and CD8+ T cells [124, 125, 
137, 138]. Monocytes, neutrophils and platelets are redundant in effector phase of 
ECM development but have been implicated in the early stage of infection through 
their interactions with brain endothelial cells as well as in terms of cytokine 
production [125, 139-141]. The role of NK cells in ECM progression is widely 
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debated. In one study depletion with anti-Asialo GM1 prevented ECM development 
by decreasing the CD8+ T cells migration to the brain [142], whereas another study 
showed that treatment with anti-NK1.1 showed no effect [143]. Further study is 
required to elucidate the role of NK cells and explain such discrepancy.  
 
While the role of some immune subsets remains debatable, it is clear that CD8+ T 
cells, specifically ɑβCD8+ T cells, are the main effector cells causing damage in the 
BBB and mediating end-stage ECM pathology [100, 124, 143, 144]. At the time of 
ECM, only 50-100,000 CD8+ T cells were found in the brain of susceptible mice 
[124, 145]. Antibody-depletion of these CD8+ T cells population in the brain, one 
day before the onset of neurological signs, was able to abrogate ECM development 
[124, 146]. Likewise, mice deficient of CD8+ T cells when infected with PbA were 
protected from ECM death [124]. The importance of CD8+ T cells in ECM 
pathogenesis was further confirmed when ECM-resistant recombinant activating gene 
2 (Rag2)-deficient mice became susceptible to ECM after receiving adoptive 
transferred splenic CD8+ T cells from ECM mice [144].  
 
Cytotoxic CD8+ T cells depends on perforin and granzyme B (GrB) to induce 
damage in the BBB [144, 147] at multiple areas in the cortex, cerebellum and 
olfactory bulb [148, 149]. Pathogenic CD8+ T cells, particularly those that are 
parasite-specific, target brain endothelial cells that present PbA antigen [136, 150]. 
So far, a total of eight blood-stage PbA epitopes has been identified [136, 151-153]. 
The prevailing view is that brain-sequestered iRBC, mainly schizonts [133, 154], 
serves as the source of parasite antigen to the brain endothelial cells. Recently, it was 
established that brain endothelial cells, once stimulated by IFN-γ, are able to 
phagocytose parasites and process it through proteasome- and TAP-dependent 
pathways to load onto MHC class I molecules on brain endothelial cells [150]. 
Subsequently, the parasite-specific CD8+ T cells recognize parasite-derived epitopes 
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cross-presented by brain endothelial cells [150], leading to the secretion of perforin 
and GrB secretion by these CD8+ T cells into the local brain environment, thereby 
inducing breach in the BBB [144, 147, 155]..  
 
1.5.4 T cells Priming and Expansion in the Spleen 
During early stages of malaria infection, parasite-specific CD8+ T cells have been 
shown to prime and proliferate mainly in the spleen, not in the liver or lymph nodes 
[152], before migrating into the blood and brain [136] [152]. This lymphoid organ 
consists of three micro-anatomical zones with distinct functions. The red pulp is 
responsible for filtering the blood, removing senescent RBC and pathogens. The 
white pulp contains mainly of immune cells, and upon malaria infection, undergoes 
architectural changes. In certain models of murine malaria, splenectomy aggravates 
infection by prolonging and increasing the peak of parasitemia, whereas in other 
models it can abrogate sequestration within organs [156]. In PbA-infected mice, 
splenectomy protected them from ECM due to decrease in parasite sequestration [157, 
158].  
 
The immune response first encounters the malarial particles when blood carrying 
these foreign particles circulates into the spleen [159, 160]. At the interface of white 
and red pulp, termed marginal zone, dendritic cells (DC), such as CD8ɑ+ Clec9A+ 
DC [161], mature and capture malaria antigen. Pathogen-associated molecular 
patterns (PAMPs) on these antigens are identified by pattern recognition receptors 
(PRRs) on dendritic cells [162-164]. Engagement of foreign molecular patterns with 
their respective receptors activates downstream signalling and stimulates production 
of cytokines. Simultaneously, these malarial products are phagocytosed, processed 
into smaller antigenic fragments and presented to naïve T cell. Interaction between 
these activated DC and specific CD4+ T cells induces activation, proliferation, 
expansion and finally differentiation into defined subsets, depending on the cytokine 
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milieu [165]. In the case of ECM, the outcome of such interaction usually resulted in 
polarization of the activated CD4+ T cells towards a Th1 phenotype. On the other 
hand, immunogenic cross-priming of naïve CD8+ T cells by DC, in the presence of 
helper T cells [166-168], ensures effective proliferation and programming of CD8+ T 
cells for cytotoxic function [169]. Coupled with the up-regulation of chemokine 
receptors, CXCR3 and CCR5 [142, 170-172] but not CCR2 [137], splenic T cells are 
able to migrate from the spleen into the site of pathology, which is the brain in ECM. 
Figure 1.2 illustrates the proposed key events leading to ECM pathogenesis.  
 
 
Figure 1.2 Schematic diagram of ECM pathogenesis 
Infection triggers proinflammatory response which serves to clear the circulating 
parasite (1). But PbA is capable to cytoadhere to the endothelial cells in the brain and 
release malarial ligands (2). This triggers endothelial activation (3), which 
upregulates adhesion molecules enabling parasites (4) and leukocytes sequestration 
(5). Sequestered leukocytes can also produce proinflammatory cytokines leading to a 
cycle of events that promotes more sequestration and cytokine production. On the 
other hand, sequestered parasites are taken up, processed for cross-presentation by 
brain endothelial cells (6). Meanwhile in the spleen, priming of CD8+ T cells occurs 
(7) and cells migrate out to the brain (8). In the brain, effector CD8+ T cells 
recognize malarial epitope presented on MHC class I molecules and trigger its 
cytotoxic function (9). Secreted perforin and GrB induce endothelial apoptosis and 
eventually leading to extensive damage in BBB (10). (Adapted from Howland et 
al.,[173]) 
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1.6 Sensing Malarial Products in Blood-stage 
1.6.1 Types of Host Receptors 
In the presence of pathogen, immune cells sense the foreign agent through PRRs that 
recognize PAMPs on the pathogen. These PRRs can be either membrane-bound, such 
as toll-like receptors (TLRs) [174-177] and C-type lectin receptors (CLRs) [174, 178-
180]; or cytosolic, such as NOD-like receptors (NLRs) [181-183] and RIG-I like 
receptors (RLRs) [176, 184]. Out of which , TLRs are more central in the recognition 
of pathogen during innate immunity since it comprises of several members that 
recognize PAMPs ranging from nucleic acids (DNA, RNA) to bacterial products 
(LPS) [185]. So far, ten TLRs and twelve TLRs have been identified in human and 
mice respectively [186]. In both species, TLRs can be found on the cells surface 
(TLRs 1, 2, 4, 5, 6, 10 and 11) and within endosomal compartments (TLRs 3, 7, 8, 9 
and 12). In general, PRRs are uniquely expressed on different cell types thereby 
modulating the immunological repertoire elicited by different antigen. Since blood-
stage of malaria life cycle is multifaceted (merozoites, rings, trophozoite, schizonts), 
it obvious that plentiful malarial antigens can be recognized by the different types of 
PRRs to trigger the immune response [187].  
 
1.6.2 TLR-dependent Signalling Pathway 
In malaria, genetic epidemiological studies revealed that TLR polymorphism is 
associated with susceptibility to HCM. Population studies demonstrated that common 
polymorphism in TLR2, TLR4 and TLR9 can influence development of HCM [188-
190]. Homozygosity of a specific base pair deletion in the first untranslated exon of 
TLR2 amongst uncomplicated malaria children in Uganda correlated with elevated 
pro-inflammatory response that promotes higher risk to HCM development [188]. 
Similarly, a single nucleotide polymorphism in TLR9 observed amongst HCM 
children in Uganda is associated with higher level of serum IFNγ [190]. At the same 
time, a variant in TLR4 is found to correlate well with increased risk to severe 
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malaria [189]. Interestingly, another TLR4 variant amongst Iran (Baluchi) [191], 
Burundi [192], Brazil [193] and Ghana [194] revealed no association with outcome of 
malaria infection or disease severity. Such inconsistencies in results suggest that 
human populations in different region contain unique TLR single nucleotide 
polymorphism that is capable of altering HCM susceptibility.     
 
While human study does not permit further detailed investigation to determine 
specific ligands that are recognized by those TLRs, studies on murine ECM model 
enable identification of these malarial ligands and further reveal on the specific 
immune responses upon such TLR-ligand interactions. Similar to that in HCM, 
TLR2/4 is found to play a part in ECM development [110] [122]. Further study 
demonstrated that TLR2/4 recognize malarial surface protein, 
glycosylphosphatidylinositol membrane anchor (GPI) [195, 196] and TLR4, together 
with co-receptor molecules, can recognize microparticles [197, 198], host fibrinogen 
[199] and heme [200] produced during malaria infection. Absence of TLR2/4 confers 
ECM protection through an attenuated proinflammatory response [110, 122]. 
However, different model display varying degrees of reliance on TLR2/4 and their 
downstream adaptor molecule myeloid differentiation primary response gene 88 
(MyD88) to initiate response during ECM. When C57BL/6 mice were 
intraperitoneally infected with 10
6
 fresh PbA iRBC, TLR2-MyD88 signalling 
pathway was found to be essential for ECM development. Activation of this 
particular signalling pathway induced immune responses that led to infiltration of 
pathogenic T cells as well as parasite sequestration in the brain, two important 
elements essential for development of ECM. However, in this model, Coban et al., 
eliminated the involvement of TLR4 in the pathogenesis [110]. On the contrary, when 
Kordes et al., intravenously infected C57BL/6 mice with 10
4
 fresh PbA (clone 15cy1) 
iRBC, they observed a partial dependence on TLR2/4-MyD88 signalling pathway to 
trigger a proinflammatory response to cause ECM [122]. In contrast to blood-stage 
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infection, intravenous inoculation of PbA (clone 15cy1) sporozoites into C57BL/6 
mice led to ECM development that is fully dependent on TLR2/4-MyD88 pathway 
[122]. Inconsistency in the role of TLR2/4-MyD88 signalling pathway in these 
models could be due to different infection regimens or parasite strain/clones 
inoculated. Besides TLR2/4, TLR9 is also essential in ECM pathogenesis. Two 
malarial ligands have been reported to bind to TLR9: hemozoin [201, 202] and 
malarial CpG DNA [203] which will induce a systemic proinflammatory response 
[204], thereby promoting sequestration of hemozoin  in the brain [110].   
 
1.6.3 TLR-independent Signalling Pathway 
Despite all the above findings supporting TLR2/4/9 involvement during ECM, 
Lepenis et al. held a differing opinion. Intraperitoneal inoculation of PbA iRBCs that 
was maintained through alternate cyclic passage in Anopheles stephensi mosquito and 
BALB/c mice into C57BL/6 mice revealed that induction of ECM is independent of 
TLR2/4/9 [102]. Such disparity in conclusion could be attributed to the unique 
maintenance of parasite strain/clones used. Similarly, Togbe et al. also cast doubts in 
the role of TLR cascade during ECM development. In his study, C57BL/6 mice were 
infected with a cloned line of PbA tagged with GFP. Results showed that deficiency 
in TLR1, 2, 3, 4, 6, 7, 9 and their adaptor molecules, MyD88 and TIR-domain-
containing adaptor-inducing interferon-β (TRIF), did not alter survival outcome in 
ECM [120]. Once again, these conflicting results emphasized the diversity of the 
immune response to malaria infection in different animal models [115]. More 
importantly, it suggests presence of alternative, non-TLR at work and contributing in 
ECM development.  
 
Compared to studies on TLR signalling pathway in ECM development, there is 
limited research on TLR-independent signalling pathway during ECM. A study by 
Sharma et al., supported the involvement of TLR-independent signalling pathway in 
 Chapter 1 Introduction   
21 
 
ECM development when they demonstrated that in the absence of two essential TLR-
adaptor molecules, MyD88 and TRIF, the AT-rich motif in the Pf genome could still 
induce secretion of pro-inflammatory cytokines such as IFN-I, TNF-α, IL-6 and IL-
15. Induction of cytokine production was shown to be dependent on a distinct 
signalling pathway that involves cytoplasmic nucleic sensor stimulator of interferon 
genes (STING), downstream TANK-binding kinase 1 (TBK-1) and interferon 
regulatory factor (IRF) 3/7 [109]. Besides, many other nucleic sensors, such as 
melanoma differentiation-associated protein 5/mitochondrial anti-viral signalling 
protein (MDA5/MAVS), are found to be crucial in activating downstream pro-
inflammatory cytokines during infection with other strains of Plasmodium [205-209]. 
Table 1.3 summarizes on the different host receptors, malarial ligands as well as 









Malarial Ligand Mouse/ Cells Infection/ 
Stimulation 
Effect Ref. 




 fresh PbA 
(clone 15cy1) iRBC 







Essential for ECM development 
Control production of plasma IFN-γ, 
TNF-ɑ and IL-10 





passage in Anopheles 
stephensi mosquito and 
BALB/c 
Not essential for ECM development 
Regulate T cells infiltration into the 
brain 
[102] 
TLR1 GPI Knockout C57BL/6 i.p. 10
6
 PbA-GFP Not essential for ECM development 
 
[120] 




 PbA iRBC Essential for ECM development 
Induce pro-inflammatory response 







Not essential for ECM development 
 
[120] 























 PbA iRBC Not essential for ECM development [110, 122] 




Not essential for ECM development 
 
[120] 






















 PbA iRBC Essential for ECM development 
Controls secretion of serum TNF-ɑ 







Not essential for ECM development [120] 







 PbA iRBC Essential for ECM development 
Controls parasitemia 
Upregulate production of serum IFN-
γ, TNF-ɑ and IL-12p40 
Regulate infiltration of pathogenic T 
cells in brain 






 fresh PbA 
(clone 15cy1) iRBC 
Partial involvement in ECM 
development 
Control production of plasma MCP-1 






Essential for ECM development 
Induce production of plasma IFN-γ 
and MCP-1 
Controls production of plasma IL-10 
i.p. 10
6
 PbA-GFP Not essential for ECM development [120] 











STING AT-rich motif Bone marrow-derived 
macrophages, 
HEK293 cells 
Ex vivo culture Involved in ECM development 
Stimulate production of IFN-I,, TNF-






Chapter 1 Introduction 
24 
 
1.7 Interferons in ECM  
Generally, a positive PAMPs recognition will trigger a cascade of downstream 
signalling pathways leading to nuclear translocation of transcription factors such as 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), activating 
protein-1 (AP-1) and interferon regulatory factors (IRFs). These factors regulate 
transcription of inflammatory cytokines, chemokines and interferons (IFNs) [210, 
211]. IFNs are claimed to be one of the important group of cytokines first secreted 
during malaria infection. These cytokines are more well-known for their anti-viral 
properties and there are three classes of IFNs, namely, IFN-I, IFN-II and IFN-III. 
Though all IFNs share a common secondary structure, each class bind to a distinct 
multi-chain receptor complex. Upon binding, they activate downstream JAK-STAT 
pathways, driving the expression of interferon stimulated response elements (ISRE) 
and/or interferon-gamma activated sequences (GAS) elements [212], which in turn 
regulates development, host defence and signalling [213]. In the IFN-I family, there 
are 13 types of IFN-ɑ and only one IFN-β [214]. IFN-II comprises of solely 
interferon-gamma (IFN-γ) while IFN-III consists of IFNλ1, IFNλ2 and IFNλ3 [212].     
 
1.7.1 Type II Interferon (IFN-γ)  
IFN-γ regulates several compartments of the immune system such as antigen 
presentation [215-218], antimicrobial mechanism [219-221], leukocyte development 
[222] and immune cells trafficking [223, 224]. It is produced by many cell types such 
as natural killer (NK) and NKT cells during the innate response [225] and CD4+ and 
CD8+ T cells during the adaptive immune response [226]. Since IFN-γ is a major 
cytokine coordinating the host defence against a broad range of intracellular pathogen, 
it is the most widely studied cytokine in malaria infection and in ECM pathogenesis 
[125, 127, 143, 227, 228].  
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In humans, early and high level of IFN-γ responses is able to protect children in 
Papua New Guinea from symptomatic malaria [229]. Similarly, IFN-γ also displayed 
a protective role in murine Plasmodium infection through the inhibition of 
intracellular development of parasite in both hepatocytes [230-234] and RBC [235-
237]. However, high level of IFN-γ during parasite development was shown to be 
implicated with predisposition to severe malaria, in particular ECM. In the absence of 
IFN-γ (gene deficiency or through antibody depletion) [117, 143] or its receptor 
(IFN-γR) [114, 127], mice were protected against ECM. Moreover, serum IFN-γ 
boosts trafficking of T cells, including pathogenic CD8+ T cells, to the brain [121, 
125]. In the brain, IFN-γ signalling upregulates expression of adhesion molecules and 
therefore promoting parasite and leukocytes sequestration in the brain microvessels 
[127]. At the same time, IFN-γ is needed to drive parasite antigen presentation by 
brain microvessels cells which are targeted by pathogenic CD8+ T cells to induce 
BBB damage [150] Therefore, IFN-γ is a double edged sword which promotes 
protective immunity as well as ECM pathogenesis. Its effect as a protective or 
harmful elements lies upon the time, level and location of its production [106].  
 
1.7.2 Type I Interferon (IFN-ɑ/β)  
IFN-I regulates various immune mechanisms such as MHC expression [238], antigen 
presentation [238] and T-cell expansion [239, 240]. It can be produced by almost any 
cell types in response to external stimulation. This cytokine is renowned for its anti-
viral properties as it is the earliest cytokine produced in response to viral infection in 
order to limit initial viral replication prior to mounting of an effective adaptive 
immune response. IFN-I are known to modulate IFN-γ production [241] and prime 
IFN-γ-mediated immune responses [242]. A recent transcriptome analysis of the liver 
obtained from PbA [208] sporozoite-infected C57BL/6 or BALB/c mice revealed that 
genes linked to IFN signalling were upregulated.  




Polymorphism in the receptor of interferon-ɑ/β receptor (IFNAR) amongst the human 
population is robustly associated with progression of HCM [119, 243]. In Malawi, 
higher expression of genes involved in interferon pathway was found in peripheral 
blood mononuclear cells of children recovering from severe malaria [244]. In murine 
model, mice treated with recombinant IFN-ɑ [245] or IFN-β [112] were shown to be 
resistant to ECM. However, endogenous IFN-I induced during Plasmodium infection 
plays a pathogenic role in ECM development. Absence of IFN-I signalling, in mice 
deficient of IFNAR, either delayed [123] or fully protected [118, 119] the mice from 
ECM death. Haque et al. [118] revealed this protection is a consequence of a 
restrained parasite growth in the deficiency in IFN-I signalling, whereas Ball et al. 
[119] and Palomo et al. [123] concluded that absence of IFN-I pathway reduced 
sequestration of pathogenic T cells in the brain. Taken together, it seems that the 
effect of IFN-I in ECM remain inconclusive and it seems possible that effects of IFN-
I rely on precise level and timing of expression.   
 
1.7.3 Crosstalk between IFN-I and IFN-γ  
Although IFN-I and IFN-II (IFN-γ) play distinct roles in the immune response, there 
are evidences supporting an intimate crosstalk between these two cytokines. For 
instance, IFN-I can modulate production of IFN-γ [241] and prime IFN-γ-mediated 
immune responses [242], and when absent prevented optimal protective IFN-γ 
response [246, 247]. Furthermore, during Plasmodium infection, treatment with IFN-
ɑ inhibits parasite development in the blood stage and promotes better survival 
outcome. The effect of IFN-ɑ on the control of parasite growth was later found to rely 
on IFN-γ [248]. On the other hand, IFN-β treatment was demonstrated to suppress 
IFN-γ production, together with chemokine CXCL9 and receptor CXCR3 expression, 
thereby preventing ECM death [112]. These suggest that IFN-I signalling can indeed 
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affect IFN-γ secretion and consequently its immune response during ECM 
development. 
 
1.8 Interferon Regulatory Factors  in ECM 
1.8.1 Function of IRFs 
As discussed above, malarial ligands are recognized by different receptors, which 
trigger the production of IFNs or other cytokines. Generally, recognition of PAMPs 
or damage-associated molecular pattern molecules (DAMPs) by endolysosomal TLRs 
(TLR2, TLR3, TLR4, TLR7, TLR8, TLR9) [84, 249-251], cytosolic RLRs [252], 
DNA-dependent activator of IRFs (DAI) and nucleotide-binding oligomerization 
domain-2 (NOD2), can activate IRF for IFN-I production. Numerous types of host 
receptors and downstream signalling molecules can be involved in pathogen sensing. 
However, only a few downstream transcription factors, like the IRFs, will regulate the 
gene expression of IFNs. There are nine members in the IRFs family namely IRF1-9. 
Each IRF binds to a unique set of ISRE to stimulate transcription of diverse genes 
that are translated into functional proteins [253, 254]. The roles of a few IRFs in both 
human and murine ECM development are summarized in Table 1.5.       
Table 1.5 Diverse roles of different IRFs in ECM development 
IRF Host 
/Model 
Infection Functions Ref. 
IRF1 Human P.falciparum Control parasitemia [255] 
Not involved in development 
of severe malaria 
[256] 












T cells numbers  
[113] 





Mice PbA iRBCs Involved in ECM 
development 
[109] 
IRF7 Mice PbA iRBCs Play a role in ECM [103, 108] 




IRF8 Mice PbA iRBCs Play a role in ECM 
development  
[126] 
Regulate production of 
proinflammatory cytokines  
Mediate IFN-I production 
Control antigen processing 
and presentation and 
chemotaxis 
[113] 




1.8.2 Interferon Regulatory Factor 1  
IRF1 is the first member of the IRF family identified to bind to the promoter region 
of IFN-β and expressed in many cells types. It mediates production of both IFN-I and 
IFN-γ, which can strongly induce IRF1 and IFN-γ in a positive feedback loop. 
Besides, it also regulates antigen presentation, monocyte/macrophage differentiation, 
T cell development, B cell growth [258], and promotes Th1 response [259]. Human 
genetic studies demonstrated that the IRF1 gene is located in chromosome 5q31-33 
region and variation in this region is associated with control of parasite density during 
Pf erythrocytic infection [260]. Subsequent study showed that polymorphisms in 
IRF1 gene could lead to differential abilities to control Pf infection amongst the West 
African ethnic groups [255]. However, the same group found that polymorphisms in 
this transcription factor does not correlated well with susceptibility in the 
development of severe malaria pathology amongst African children [256].  
In murine malaria model, IRF1 was shown to be essential for ECM development. 
Absence of this transcription factor in either 6 to 8 weeks old [257] or 9 to 14 weeks 
old [107] C57BL/6 mice infected with 10
6 
PbA intraperitoneally, displayed better 
ECM outcome, indicating that IRF1 is essential in ECM development. Interestingly, 
while 6 to 8 weeks old mice deficient of IRF1 displayed lower parasitemia [257], the 
9 to 14 weeks old mice displayed debilitated control in parasite growth [107], 
suggesting that age of mice might also plays a part in altering immune response to 
malaria infection. Microarray analysis of brains revealed a higher expression of IRF1 
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in ECM-susceptible C57BL/6 mice as compared to ECM-resistant BALB/c mice, 
[103]. Similarly, IRF1 gene expression was higher in brain of CBA/T6 mice infected 
with ECM-causing PbA parasite than with non-ECM causing P. berghei K173 
parasite [126]. Since IRF1 regulates production of IFN-γ and IL-12p40, as well as 
control the number of CD8+ T cells during PbA infection [113], it is not surprising 
that ECM-susceptible mice has higher level of IRF1 expression  than –resistant mice. 
IRF1 also plays a role in antigen presentation [258], an essential component in ECM 
pathogenesis. Therefore, it is possible that the effect of IRF1 in ECM development is 
more far-reaching, and further studies are needed to investigate the exact implication 
of IRF1 in shaping the immune defence during ECM.  
 
1.8.3 Interferon Regulatory Factor 3/7  
IRF3 and IRF7 work hand-in-hand to drive the initial transcription of IFN-I during 
early stage of infection. Induction of IFN-I is generated through a biphasic 
mechanism in order to guarantee transcriptional efficiency and diversity of targeted 
genes. IRF3 is constitutively expressed in the cytosolic domain of all cells and resides 
as an inactive form. Upon phosphorylation, activated IRF3 undergoes nuclear 
translocation and forms a complex with NF-kB and AP-1 [261], which will lead to 
IFN-β transcription [262-264]. On the other hand, IRF7 is expressed at very low 
levels in the cytoplasm of most cells. Later in the secondary phase of IFN-I signalling, 
IFN-β signals through IFNAR to increase induction of IRF7 expression. Like IRF3, it 
undergoes nuclear translocation and forms heterodimer with IRF3 to bind with ISRE. 
Unlike IRF3, IRF7 induces maximal transcription of both IFN-ɑ and IFN-β [265]. 
Mice double deficient for IRF3/IRF7 infected with PbA were found to be protected 
from ECM death [109] confirming the role of either both or one of the IRF in ECM 
pathogenesis. Furthermore, microarray analysis of brain displayed higher 
transcriptional activity of IRF7 in ECM-susceptible mice than ECM-resistant [103] 
and uninfected control mice [108], suggesting a possible role of IRF7 in ECM 
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development. However, the exact role of IRF3 and IRF7 in malaria remains poorly 
defined.  
 
1.8.4 Other IRFs 
Apart from IRF1, IRF3 and IRF7, the involvement of some other transcription factors, 
such as IRF8 and IRF9, in shaping the immune response during ECM were also 
investigated. 
 
IRF8 is an unique transcription factor that is only expressed in immune cell [266] and 
its expression is solely regulated by IFN-γ [267]. Collaborative effort of IRF1 and 
IRF8 is shown to direct the transcription program in immune cells towards a Th-1 
dominated response [268]. Amplification of IRF8 gene expression was observed in 
the brains of ECM-susceptible PbA-infected CBA/T6 mice, [126]. Mice bearing a 
dysfunctional IRF8 were protected from ECM death due to down-regulated 
expression of many IRF8 dependent genes that triggers ECM development. These 
genes are found to be involved in antigen processing and presentation, chemotaxis 
and production of pro-inflammatory cytokines [113]. Although these results suggest 
that IRF8 is crucial in ECM development, more studies are required to ascertain its 
specific role in HCM. 
 
IRF9 expressed constitutively in many cells types, unlike the other IRFs, dimerize 
with STAT1 and STAT2 to form an active trimeric complex, known as ISGF3 [269, 
270]. Expression of ISGF3 was observed in the brain of ECM-susceptible mice and it 
was shown that its amplification is dependent on IRF8 [113]. This hints that the 
trimeric complex also plays a role in contributing to ECM development, albeit under 
the control of IRF8-dependent response.  
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Figure 1.3 depicts the different ligands, distinct signalling pathways and downstream 
IRFs involved in response to malarial infection.  
 
 
Figure 1.3 Diagram for ECM-induced signalling pathway 
Blood-stage malarial ligands are recognized by various host receptors which triggers 
distinct downstream signalling pathways during ECM development. TLR4 on the 
surface recognizes a number of malarial ligands such as GPI, microparticles, host 
fibrinogen and heme (in the presence of co-adaptor molecule). TLR2, together with 
either TLR1 or TLR6 recognize GPI. Within the endosomal compartment, TLR9 
recognize hemozoin and CpG DNA. Heterodimer TLR7/TLR9 has been proposed to 
recognize an unknown malarial ligand. Interactions of ligand-receptor trigger 2 
proposed pathways. (1) TLR-dependent pathway involving MyD88 phosphorylates 
downstream signalling molecules which induce nuclear translocation of NF-𝜅B 
(nuclear factor kappa-light-chain-enhancer of activated B cells and AP-1, stimulating 
production of proinflammatory cytokines. At the same time, phosphorylated kinases 
or MyD88 induce activation of IRF3 and IRF7 to transcribe IFN-I and ISGs. (2) 
Activation of TLR-independent pathway triggered by AT-rich motif present within 
plasmodial genome engages STING, TBK, IRF3, and IRF7. (Adapted from Gun et al., 
[187])  
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Aim of the thesis 
The pro-inflammatory milieu induced during infection is initiated through the sensing 
of malarial products. As mentioned above, all signalling pathway regardless of the 
host receptors or downstream molecules converge on the activation of transcription 
factors, such as NF-κB, AP-1 and IRFs. Out of which, IRFs comprise of nine 
members with each factor regulating various compartments of the immune system. 
Most importantly, they are pivotal in the production of IFNs which are essential for 
ECM development. In this project, we are interested to understand the mechanism on 
how each IRF (IRF1, IRF3 and IRF7), alone, could shape the immune response and 
affect the ECM outcome. 
 
1.9 Key Objectives 
1. Assess the ECM outcome and extent of brain pathology in the absence of 
each IRF. 
2. Determine which parameter (parasitemia, parasite sequestration, leukocytes 
sequestration and antigen presentation) change in the absence of each IRF. 
3. Perform mechanistic study to understand the effect of absence of IRF on the 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 Animals 
All mice were derived from C57BL/6 genetic background. Female or male wild-type 
(WT) C57BL/6, IFNARKO and IRF1KO
 
were purchased from The Jackson 
Laboratory. IRF3KO and IRF7KO
 
mice were obtained from Riken, Japan. IRF3.IRF7 
double knock-out mice (DKO) were generated by crossing IRF3KO mice with 
IRF7KO mice. Genotyping was performed to confirm mouse genetic makeup. IRF1 
F1 and IRF3 FI were generated by crossing IRF1KO or IRF3KO with WT C57BL/6 
mice. All mice (5-8 weeks old) mice were bred and maintained under specific 
pathogen-free conditions in the Biomedical Resource Centre, Singapore. All 
experimental procedures were conducted in accordance to the rules of Agri-Food and 
Veterinary Authority and National Advisory Committee for Laboratory Animal 
Research, and with the approval of BRC Institutional Animal Care and Use 
Committee.  
  
2.2 Bone Marrow Reconstitution 
Two femurs and two tibias were harvested from naïve donor WT mice. Bones were 
submerged in chimera buffer, comprising of 0.5mM EDTA (Sigma) and 3% heat-
inactivated fetal bovine serum (HI-FBS) (Life Technologies) in PBS. In a sterile hood, 
the ends of the bones were snipped off and bone marrow cells within were flushed out 
with ice-cold sterile chimera buffer in a syringe fitted with 21G-needle. Cells were 
underlay with 1ml HI-FBS and centrifuged at 1500rpm with no brake for 6mins at 
4
o
C. After treatment with Ammonium-Chloride-Potassium (ACK) lysis buffer 
(155mM NH4Cl, 10mM KHCO3, 0.2mM EDTA, Sigma-Aldrich), bone marrow cells 
were once again underlay with 1ml HI-FBS and washed. Subsequently, cells were 
resuspended in 10ml chimera buffer and filtered through 70µm cell strainer (BD 
Bioscience, San Jose, CA). After washing, bone marrow cells were counted to make 
up a concentration of 2 x 10
7
 cells/ml. Prior to injection, clumped cells were removed 
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by filtering through 70µm cell strainer. Recipient WT and IRF3KO mice irradiated at 
550 Rad twice (2.5h apart), were intravenously injected with 4 x 10
6
 cells/ml of bone 
marrow cells via the retro-orbital sinus. 6 weeks later, reconstitution was assessed 
through genotyping of peripheral blood samples.     
 
2.3 Infection and Assessment of ECM Pathology  
Transgenic Plasmodium berghei ANKA (231c11) line which expresses luciferase and 
green fluorescent proteins under the control of efl-ɑ (PbAluc) was kindly provided by 
Dr. Christian Engwerda (QIMR, Brisbane, Australia). Cryo-frozen parasite stocks 
were prepared through in vivo passage in C57BL/6 mice and free from other 
infectious agents. Infection is initiated through intraperitoneal injection of 10
6
 PbAluc 
infected red blood cells (iRBC), unless otherwise stated. Mice were considered 
suffering from ECM when they display any of the following neurological signs: 
paralysis, ataxia, deviation of head, convulsion and/or coma. Such signs were 
typically observed between 6 and 12 day post-infection (dpi). Mice that did not 
succumb to ECM will die later of hyperparasitemia and anaemia. Cumulative ECM 
incidence represented the number of mice that displayed ECM signs throughout 
infection.    
 
2.4 IL-10 Receptor Antibody Treatment 
Mice were injected with rat ɑ-mouse IL-10 receptor monoclonal antibody (Clone 
1B1.3A; BioXcell) or rat IgG control antibody (Sigma). Treatment begun with 0.3mg 
injected intraperitoneally on -1 dpi (one day prior to infection), followed by 0.2mg on 
1, 4, 6 dpi.   
 
2.5 Histology 
Infected mice were sacrificed on 7dpi. Mice were anaesthetized and then perfused 
with PBS followed by 4% formaldehyde (VWR). Brain was immediately removed 
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and submerged in 4% formaldehyde. Paraffin-embedded brain was sagittal sectioned 
and stained with haematoxylin and eosin (H&E). Each section is 5µm in thickness. 
Slides were acquired on Metafer4 (MetaSystems).  
 
2.6 Assessment of Parasitemia 
Parasitemia was monitored daily from 3 to 12 dpi and afterwards every 2-3 dpi. 
Mouse blood samples were collected via tail bleed and stained with Hoechst 33342 
(Sigma Aldrich), Dihydroethidium (Sigma Aldrich) and anti-mouse CD45 coupled to 
APC (Miltenyi Biotec Asia) for 20mins at room temperature in the dark. After 
incubation, 500ul of PBS was added. Samples were acquired using LSR II flow 
cytometer (BD). To define the threshold of positivity for parasitemia, blood samples 
from naïve WT were taken and tested in parallel every time. All data analyses were 
performed using FlowJo (Tree Star). 
 
2.7 Evans Blue Extravasation Assay 
To assess the integrity of BBB, permeation of Evans Blue in the brain tissues was 
measured. 200ul of 1% Evans Blue, diluted in 0.9% NaCl, was injected intravenously 
into the mice and allowed to circulate for an hour. Following that, the mice were 
exsanguinated and the brain extracted to be immersed in 1ml N, N-
Dimethylformamide (Sigma) overnight. Extent of cerebral vascular leakage was 
quantified by measuring the absorbance of DMF extracts of Evans Blue at OD620nm 
which was normalized to brain weight.     
   
2.8 Bioluminescence Imaging Studies 
Substrate D-Luciferin potassium salt (Caliper Life Science) was dissolved in 
phosphate-buffered saline (PBS) to make up a concentration of 5mg/ml and kept in 
the dark. For imaging, mice were anaesthetized in oxygen-rich induction chamber 
with 2% isoflurane and injected with 100ug D-Luciferin subcutaneously. 
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Bioluminescence signal was captured by the imaging machine (IVIS, Xenogen, 
Alameda, California). All imaging were acquired at medium binning factor and f/stop 
1. Bioluminescence signal exceeding 62000 units was considered saturated. All data 
analysis was performed using software Living Imaging 3.0 to obtain an average 
radiance (photons/s/cm
2
/sr). To remove background signals, bioluminescence signals 
of naïve WT mice were subtracted from all data.   
 
2.8.1 In vivo Imaging 
To quantify the amount of parasite accumulation in whole body and head throughout 
the infection, in vivo imaging (IVIS, Xenogen, Alameda, California) was performed 
daily from 5 dpi onwards. After 2mins of substrate circulation, anesthetized mice 
were placed on the acquisition stage within the imaging machine. Whole body 
imaging was performed on animals in ventral position (facing the camera) at 12.5 x 
12.5cm field of vision (FOV: distance between the camera and the sample stage). 
Head imaging was performed on animals on dorsal position (back of head facing the 
camera) at 7.5 x 7.5cm FOV. Exposure time ranges from 5 to 60s, depending on the 
intensity of the bioluminescence signal. 
 
2.8.2 Ex vivo Imaging 
To quantify the amount of parasite accumulation in organs, ex vivo imaging was 
performed on 7 dpi. Mice were anesthetized and injected with substrate D-Luciferin. 
2mins after substrate circulation, anesthetized mice were perfused intracardially with 
PBS to remove circulating blood. The brain was first to be extracted and placed in a 
petri dish. Immediately, 2-3 drops of D-Luciferin were dripped on the brain and 
imaged. Subsequently, other organs such as lungs, heart and spleen were extracted 
and rinsed in PBS. Following that, all organs were placed in the same petri dish as the 
brain and imaged again. Organs imaging was performed at 10 x 10cm FOV with 
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exposure time of 5s, 10s, 30s, and 60s. Images with the highest bioluminescence 
signal, but lower than 62000 units, was analysed.      
 
2.9 Leukocytes Isolation 
Mice were anaesthetized and perfused intracardially with PBS to remove circulating 
blood and leukocytes. Following that, brain and spleen were dissected and separately 
placed in RPMI-1640 (BSF, A*STAR), supplemented with 10% HI-FBS and 
100U/ml Penicillin/Streptomycin (Gibco, Life Technologies). Brain and spleen were 
mashed through 100µm and 40µm cell strainer (BD, Bioscience, San Jose, CA) 
respectively. To isolate brain-sequestered leukocytes (BSL), brain samples were 
digested with 10µg/ml Collagenase Type IV (Worthington Biochemical, Lakewood, 
NJ), 0.5mg/ml DNase I (Roche) in 10ml PBS for 30mins at room temperature and 
filtered through 40µm cell strainer. After a brief centrifugation at 500rpm for 1min to 
remove large debris, the supernatant was layered over a 30% Percoll gradient and 
centrifuged at 3000rpm for 10mins. Subsequently, the pellet was lysed with ACK 
lysis buffer and washed with RPMI medium. To isolate splenocytes, spleen samples 
were centrifuged at 1500rpm for 5mins and the pellet was treated with ACK lysing 
buffer and washed. To isolate dendritic cells, spleen samples were digested with 
100U/ml DNase I, 0.1mg/ml Collagenase IV in 3ml RPMI medium for 1h at 37
o
C. 
Digested splenocytes were homogenize with 19G syringe needle and filtered through 
70µm cell strainer. Next, the cell suspension was centrifuged at 1500rom for 5mins 
and the pellet was treated with ACK lysing buffer and washed. Cell number was 
counted using haemocytometer.  
 
2.10 Flow Cytometry Analyses 
2.10.1 Surface Staining 
To stain for live cells, samples were stained with LIVE/DEAD Fixable Aqua stain 
(Life Technologies) for 30mins at room temperature. After incubation, cells were 
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centrifuged to remove supernatant and stained with H-2D
b
-Pb1 (SQLLNAKYL)-PE 
or -APC tetramers in blocking buffer (FACS buffer, Mouse serum, Rat serum, 
Hamster Serum) for 25mins on ice. Next, ɑCD45.2-PerCP-Cy5.5 (Clone 104, 
eBioscience), ɑCD45-APC (Clone 30F11, MACS), ɑCD3e-PE-Cy7 (Clone 145-2C11, 
BD Pharmingen), ɑCD4-Pacific Blue (Clone RM4-5, Biolegend), ɑCD8a-Brilliant 
Violet 605 (Clone 53-6.7, Biolegend), ɑCXCR3-PerCP Cy5.5 (Clone CXCR3-173, 
eBioscience), ɑNK1.1-APC (Clone PK136, eBioscience), ɑCD11a-FITC (Clone 
M17/4, eBioscience), ɑCD11b-PerCp-Cy5.5 (Clone M1/70, eBioscience), ɑCD11c-
Pe Cy7 (Clone N418, eBioscience), ɑCD69-PE (Clone H1.2F3, BD Pharmingen) 
were added accordingly to stain for 20mins on ice. After that, samples were 
centrifuged at 1500rpm for 5mins at 4
o
C and pellet was resuspended in FACS buffer 
ready for acquisition on LSR Fortessa (BD Bioscience). Single stains were first used 
to determine settings and voltage. Following that, fluorescence minus one (FMO) 
control was utilized to validate specific antibody staining.  
 
2.10.2 Intracellular Staining 
Whole population of BSL or 5x10
6
 splenocytes were incubated with 10µg/ml 
Brefeldin A (eBioscience) in 1ml RPMI medium at 37
o
C for 3h before surface 
staining. After washing the cells of excess antibody, samples were fixed in 2% 
formaldehyde and kept overnight at 4
o
C. The next day, cells were permeabilised with 
0.5% w/v saponin (Sigma Aldrich) and stained with ɑIFNγ-PerCP Cy5.5 (Clone 
XMG1.2, eBioscience), ɑGranzyme B-Pe Cy7 (Clone NGZB, eBioscience), ɑT-bet-
AlexaFluor 647 (eBio4B10, eBioscience) or ɑPD-1-PE (Clone J43, BD Pharmingen) 
for 20mins on ice. Thereafter, cells were washed and suspended in FACS buffer for 
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2.11 In vivo Cytotoxicity Assay 
Naïve donor mice were sacrifice for the spleen. After ACK lysis, naïve splenocytes 
were divided into 2 portions of 4 x 10
7
cells/ml. One portion was pulsed with 10µg/ml 
Pb1 peptide for 1h at 37
o
C and then stained with 0.5µM CFSE (Sigma) for 10mins at 
37
o
C. The other portion remained unpulsed and stained with 5µM CFSE for 10mins 
at 37
o
C. Thorough staining was achieved by mixing the splenocytes periodically 
during staining. To quench the staining, 5ml warm RPMI medium was added and 
subsequently splenocytes were washed twice with cold medium. Next, splenocytes 
were counted and resuspended in PBS to make up 6.67 x 10
7
 cells/ml. Equal volume 
of pulsed and unpulsed cells were combined and filtered through a 40µm cell strainer. 
These donor splenocytes, 10
7
 cells from each portion, were injected intravenously 
into naïve mice and infected mice on 6 dpi. 20h later, recipient mice were euthanized 
and splenocytes were harvested for FACS analysis. Capacity of in vivo killing was 
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2.12 Ex vivo Brain Microvessels Cross-presentation Assay 
Anaesthetized mice were exsanguinated on 8dpi. Brain was immediately dissected 
and placed in 1ml RPMI complete medium, supplemented with 10% HI-FBS, 
100U/ml Pen/Strep, 55µM 2-mercaptoethanol, 1mM sodium pyruvate (Gibco, Life 
Technologies) and 100µg/ml Primocin (Invitrogen). The brain was minced to 
approximately 1mm in size and homogenized 5 times with a 23-gauge needle. Next 
the brain suspension was split into 2 portions and equal volume of 30% Dextran (MW 
~70,000, Sigma Aldrich), diluted in PBS, was added and mixed well for 
centrifugation at 10,000g for 15mins at 4
o
C. After removing the supernatant, the cell 
pellet was resuspended in PBS and combined. This suspension was drain through a 
40µm cell strainer to retain the brain microvessels. Cell strainers were then inverted 
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over a 6-well plate (Thermo Scientific) and back flushed with PBS to collect these 
brain microvessels. 2% HI-FBS 10µg.ml DNase I and 1mg/ml Collagenase IV were 
then added and the brain microvessels were rocked gently for 90mins at room 
temperature. Following digestion, the microvessels were transferred to a falcon tube 
with 5ml complete medium and spun down at 1500rpm for 5mins. The pellet was 
resuspended in 500µl complete medium and divided between 5 wells in a 96-well 
filter plate. Brain microvessels were incubated overnight with 3 x 10
4 
LR-BSL8.4a 
cells in each well. The next day, the cells were fixed with 2% Formaldehdye and 0.2% 
Glutaraldehyde diluted in water for 5mins, and subsequently, stained with 5mM 
Potassium Ferricynate and Ferrocynate, 2mM MgCl2 and 1mg/ml X-gal diluted in 
PBS for 6h at 37
o
C. Figure 2.1 represents a schematic for the brain microvessels 
assay. Image of each well was acquired on CTL ImmunoSpot Analyser. Each blue 
spot, representing an activated LR-BSL8.4a cell, was then manually counted. Total 
number of blue spots was added up in the 5 wells and data was log transformed.   
 
Figure 2.1 Schematic diagram to illustrate procedures in brain microvessels assay 
(adapted from Howland et al., 2013) 
 
2.13 Peptide Pulsing on Brain Endothelial Cells 





 binding chicken ovalbumin OVA257-264-peptide (SIINFEKL; 
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MW = 963 Da) peptide diluted in Dimethyl Sulfoxide for 1h at 37
o
C. After washing, 
3 x 10
4 
OT-1 reporter cells were added for overnight incubation and stained with X-
gal on the next day.  
 
2.14 Culture of Naïve Brain Endothelial Cells 
Isolation of brain microvessels from naïve mice followed protocol as described in ex 
vivo brain microvessels assay. However, Collagenase IV/DNase I digestion was 
extended to 3h at 37
o
C instead. Following that, digested brain microvessels fragments 
were washed with DMEM complete medium (BSF, A*STAR) twice. After final wash, 
pellet was resuspended in endothelial medium (DMEM medium complete with MEM 
non-essential amino acids, 0.1mg.ml heparin and 0.1mg.ml endothelial cell growth 
supplement (Corning)), together with 4µg/ml puromycin. Suspension was seeded in 
collagen coated 48-well plate. Usually 5 mice brains were used to seed in 32 wells. In 
the morning of the 3
rd
 day, the medium was replaced (without puromycin) and 
changed every 3-4 days thereafter.   
 
2.15 In vitro Brain Microvessels Cross-presentation Assay 
Cultured brain endothelial cells were stimulated with either recombinant mouse IFN-
γ (R&D Systems or recombinant mouse IFN-β (Millipore) 24h before 5 x 106 freeze-
thawed PbAluc mature iRBCs were added. 24h later, brain endothelial cells were 
washed followed by adding 6 x 10
4
 reporter cells in 0.4ml RPMI complete medium. 
After overnight incubation, reporter cells were resuspended and transferred to a 96-
well filter plate for X-gal staining as previously described.   
 
2.16 Serum Collection  
Mice were bled for small volume via retro-orbital bleeding or terminally bled via 
cardiac puncture on 0 and 7 dpi. Blood samples were left standing for at least 5h at 
room temperature before spinning down at 8000rpm for 10mins. Supernatant was 
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2.17 Enzyme-linked Immunosorbent Assay (ELISA) 
2.17.1 IFN-γ ELISA 
Concentration of IFNγ in the serum was quantified using Mouse IFNγ Quantikine 
ELISA kit (R&D Systems). Briefly, ELISA plate was loaded with the given Assay 
Diluent before standards and samples were added in duplicates. Serums from infected 
mice were diluted at 4x whereas no dilution was performed for naïve samples. After 
2h incubation, wells were washed 5x with Wash buffer provided and incubated with 
mouse IFNγ Conjugate for 2h. Subsequently, the wells were washed again and 
substrate solution was added and kept in the dark for 30mins. Enzymatic reaction was 
terminated by adding stop solution and absorbance was recorded at 450nm on 
microplate reader (EnSpire® PerkinElmer). After subtracting the background, 
standard curve was plotted and an equation for best fit line was derived. 
Concentration of IFNγ was then calculated and units expressed as ng/ml.  
 
2.17.2 IL-10 ELISA 
Concentration of IL-10 was quantified with Mouse IL-10 Quantikine ELISA kit 
(R&D Systems). Briefly, Assay Diluent was added to the wells before addition of 
standards and samples. Both standards and samples were run in duplicates. Serum 
obtained from infected mice were diluted 5x. The plate was then placed in a 
horizontal orbital microplate shaker for 2h at 500rpm. After washing the plate for 5x, 
mouse IL-10 conjugate was added and returned to the shaker for 2h. After the second 
wash, substrate solution was added and incubated in the dark for 30mins. Stop 
solution was finally added to terminate further development and the plate is recorded 
at 450nm on microplate reader (EnSpire® PerkinElmer). After subtracting for 
background of the plate, standard curve was plotted and an equation for best fit line 
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was derived. Using the equation, the concentration of IL-10 was calculated and 
expressed as ng/ml.   
 
2.17.3 IFN-ɑ ELISA 
Concentration of IFN-ɑ was quantified using cytometric beads (FlowCytomixTM, 
eBioscience). Briefly, samples diluted in Assay Buffer were added to the plate and 
incubated in the dark. After washing the plate for 3x, detection antibodies were added 
and incubated for 30mins. Plate was washed again and Streptavidin tagged with PE 
was added for 30mins in the dark. After the final wash, beads were resuspended in 
Reading Buffer. Plate was left to shake for 5mins before acquiring data on 
FACSarray analyser. Data were processed with FCAP array software (BD 
Biosciences).   
 
2.18 Total RNA Extraction and Real-time Quantification PCR (RT-qPCR) 
Anaesthetized mice were perfused intracardially with PBS followed by brain and 
spleen extraction. Organs isolated were submerged in 200ul TRIzol reagent (Life 
Technologies) and frozen at -80
o
C. Total RNA was isolated from tissue using a 
phenol-chloroform method. Briefly, organs frozen in TRIzol reagents were thawed 
and more TRIzol reagent was added before the content was transferred to 
gentleMACS M tubes (Miltenyi Biotec). Tissues were disrupted and homogenized 
using a rotor-stator homogenizer (Xiril Dispomix) at 3000rpm for 15s. Homogenized 
tissues were transferred into Eppendorf tubes where chloroform was added and 
vigorously shaken for 15s, then allowed to stand for 2mins. Samples were centrifuged 
at 12000rpm for 15mins at 4
o
C and the aqueous phase was obtained for RNA 
extraction using RNeasy Mini Kit (QIAGEN) as manufacturer’s instructions. 
Extracted RNA was diluted to approximately 10ng/ml with RNase-free water (Qiagen) 
using Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific).      
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RT-qPCR was performed in duplicates for each protein of interest using QuantiFast 
SYBR Green RT-PCR kit (QIAGEN). Reaction mixture comprising of 1.0ul of 
10ng/ml RNA, 6.25ul of QuantiFast SYBR Green RT-PCR master mix, 0.625ul of 
10µM forwards and reverse primers (Table 1), 0.125ul of QuantiFast RT mix and 
4.5ul of RNase-free water was prepared in 384-well plate and RT-qPCR was 
performed using Applied Biosystems 7900HT Fast Real-Time PCR System. Reaction 
conditions were set as the following: (a) 50
o
C for 10mins; (b) 95
o
C for 5mins; (c) 40 
cycles of a 2-step reaction consisting of 95
o
C for 10s followed by 60
o
C for 30s. Upon 
completion of the run, data were exported into Microsoft Excel 2010, normalized to 
GAPDH and analysed using the ΔΔCT method. ΔΔCT was obtained by subtracting 
average ΔCT of naïve mice from ΔCT of infected mice of the same genotype. Fold 
change of each gene was then calculated as 2
Δ ΔCT
.    
 
Table 2.1 Primer sequences for RT-qPCR (5’-3’) 
Gene Forward Primer Reverse Primer 






Mouse IFNγ ATGAACGCTACACACTGCATC CCATCCTTTTGCCAGTTCCTC 
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2.19 Statistical Analysis 
Statistical analyses were performed in Prism 6 (GraphPad Software, Inc.). Survival of 
ECM was assessed using log-rank Mantel-Cox test. Data from Evans Blue 
extravasation assay, leukocytes immunophenotyping, ELISA, RT-qPCR and in vivo 
cytolytic assay were analysed for normality using column statistics. If results follow a 
normal distribution, Student’s T-test would be employed; otherwise, Wilcoxon-
Mann-Whitney test would be utilized. Values from parasitemia, imaging studies and 
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CHAPTER 3  
MODULATION OF IFN-γ/IL-10 RATIO BY INTERFERON REGULATORY 
FACTOR 1 DETERMINES ECM SUSCEPTIBILITY 
 
3.1 Introduction 
Interferon Regulatory Factor 1 (IRF1) is a transcriptional factor expressed 
constitutively at low level in many cells types [253]. Upon activation, it mediates the 
production of IFN-II, as well as promotes Th1 response [259]. On the other hand, the 
role of IRF1 in the regulation of IFN-I genes remains controversial as cells deficient 
of IRF1 incubated with different stimulants were shown to trigger varied IFN-I 
responses [271-273].  
 
IFN-γ signalling and Th1 differentiation were shown to be induced by IL-12 in a 
IRF1-dependent manner [274]. Besides, IRF1 also plays a role in the development of 
CD8+ T cells. However, in its absence, a skewed response towards Th2 is observed. 
In mice deficient of IRF1 (IRF1KO), there is upregulated IL-4 expression due to loss 
of IRF1-directed repression on IL-4 transcription [275], impairment of IL-12 
production [276] and hyporesponsiveness to IL-12 [277]. Moreover, these mice do 
not express TAP-1, latent membrane protein 2 (LMP-2) and MHC-I [278], leading to 
a defect in antigen presentation [279]. As a consequence of  the lack of positive signal 
required to prevent cell death during early developmental stages [271], IRF1KO mice 
exhibited defect in thymic CD8+ T cells development [271, 273, 278]. 
 
Studies done in malaria-infected patients have demonstrated that while in West 
African ethnic groups, polymorphism in IRF1 was associated with Pf infection 
clearance [255], in severe cases of malaria infected children amongst three other 
African populations, no correlation between the polymorphism and disease severity 
was observed [256]. The authors highlighted that this discrepancy is linked to the 
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highly diversified genome displayed amongst the African population. Hence, we 
should take into account the possibility that allelic variants in IRF1 could be 
associated with susceptibility to HCM.  
 
A comparative transcriptional profiling analysis in mice showed that brain of ECM-
susceptible C57BL/6 mice has higher IRF1 gene expression than ECM-resistant 
BALB/c mice [103]. Similarly, ECM-causing parasite PbA induced higher IRF1 gene 
expression in the brain of CBA/T6 mice than non-ECM causing P.berghei K173 
parasite [126]. Using IRF1KO mice, it was demonstrated that this transcription factor 
plays a role in ECM pathogenesis, and the peripheral parasitemia was different from 
WT mice [107, 113, 257]. As compared to their WT counterparts, naïve IRF1KO 
mice were found to have smaller spleen, with considerably fewer cells [107], lower 
CD8+ T cells number [113], decrease  IFN-γ mRNA expression in the brain and on 
serum protein level [113, 257]. Upon infection with PbA, IRF1KO mice were 
partially protected from ECM [107, 257]. Since CD8+ T cells [124, 125] and IFN-γ 
[114] are pivotal in ECM development, and IFN-γ is involved in controlling 
peripheral parasitemia, the impaired production of IFN-γ and reduced number of 
CD8+ T cells in IRF1KO mice could possibly account for its ECM protection and 
varied parasitemia observed.   
 
Based on all these evidences, we aimed to further investigate the exact implication of 
IRF1 in these various immune mechanisms essential for ECM pathogenesis.  
     
 
   
3.2 Results 
3.2.1 IRF1 is crucial for ECM development 
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To confirm the importance of IRF1 in ECM development, WT and IRF1KO mice 
were infected with PbAluc and monitored for neurological signs and survival daily. 
While 100% of WT mice succumbed to ECM within 7-12 dpi, only 2 out of 27 
IRF1KO mice died within the same period (Figure 3.1A). During the course of 
infection, approximately 90% of IRF1KO mice developed neurological signs (Figure 
3.1B) though only 15% died of ECM. Our data is consistent with previous reports 
that have also shown protection from ECM death in PbA-infected IRF1KO mice [107, 
257].  
 
Figure 3.1 (A) Survival (%) and (B) cumulative ECM incidence (%) of WT 
(n=12) and IRF1KO (n=27) mice throughout infection with PbAluc. The shaded area 
in the survival curve represents days when WT mice displayed neurological 
symptoms. #p<0.05; log-rank test. Result is representative of three experiments.     
 
 
Neurological complications in ECM stems from damage in the BBB [128, 280] which 
can be assessed through histopathological examination and quantification of plasma 
protein leakage in the interstitial tissue of BBB. Since IRF1KO mice developed some 
neurological signs and yet were resistant to ECM death, we measured the extent of 
BBB damage in these mice. Histological examination of brain tissues from infected 
WT and IRF1KO mice revealed spots of cerebellar haemorrhages as compared to 
naïve mice (Figure 3.2A). Using an Evans blue dye extravasation assay, we 
demonstrated that the integrity of BBB in infected IRF1KO mice was less 
compromised than infected WT mice (Figure 3.2B and 3.2C). Overall, our data 
suggests that the damage observed in the BBB of infected IRF1KO mice was able to 
induce neurological symptoms, but not enough to lead to ECM death. 





Figure 3.2 Assessment of BBB integrity in WT and IRF1KO mice. (A) H&E-
stained brain sections of PbAluc-infected WT and IRF1KO mice on 7dpi. (B) Images 
of Evans Blue dye extravasation in whole brain and (C) quantified dye leakage in 
naïve WT (n=5), PbAluc-infected WT (n=5), naïve IRF1KO (n=5) and PbAluc-
infected IRF1KO (n=9) mice on 7dpi. Data are expressed as mean ± SD. Result of 
Evans Blue is a representative of combined data of two experiments. *p<0.05, 
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Since PbAluc-infected IRF1KO mice were protected from ECM death, we wondered 
if absence of both alleles is required for ECM resistance. To do so, IRF1KO x 
C57BL/6 (IRF1 F1) mice was generated and survival was monitored. Both WT and 
IRF1 F1 died between 8-10 dpi of ECM (Figure 3.3) indicating that both alleles need 
to be absent for ECM protection and a single functional IRF1 allele is sufficient to 
induce an immune response that leads to ECM development.  
 
Figure 3.3 Survival of WT (n=3) and IRF1 F1 (n=5) mice infected with PbAluc. 
The shaded area represented days when WT mice displayed neurological symptoms. 
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3.2.2 Control of peripheral parasite is IRF1-dependent 
The role of IRF1 in inducing an immune response for the control of circulating 
parasite is controversial. While Senaldi et al., showed that PbA-infected IRF1KO 
mice had higher parasitemia on 7dpi [107], Tan et al., demonstrated a lower peak 
parasitemia in IRF1KO mice [257]. Like Senaldi et al., we also observed an 
exponential increase in parasitemia in IRF1KO mice as compared to WT mice 
(Figure 3.4). Altogether, this data indicated that the control of parasitemia is IRF1-
dependent.    
 
Figure 3.4 Parasitemia in the blood (%) of WT (n=5) and IRF1KO (n=5) mice 
infected with PbAluc. Small amount of blood was obtained through tail bleed and 
stained using the tri-colour technique for further analysis [281]. Data are expressed as 
mean ± SD. Result is representative of three independent experiments. *p<0.05, 
**p<0.01, ***p<0.001, Unpaired Student t-test. 
 
3.2.3 IRF1 is involved in parasite accumulation during PbAluc infection 
Because peripheral parasitemia was increased in IRF1KO mice, we wonder if this 
could influence parasite accumulation in the tissues. Analysis on the parasite biomass 
by bioluminescence imaging showed that IRF1KO mice had less parasites 
accumulated in the whole body throughout infection (Figure 3.5A), whereas in the 
head, the decrease was only significant on 7dpi (Figure 3.5B).  Since in vivo imaging 
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takes into account circulating parasites and those sequestered in the tissues, we 
performed an ex vivo imaging to quantify the iRBC accumulation in isolated organs 
on 7dpi. Parasite accumulation was shown to be significantly reduced in the brain 
(Figure 3.5C) and other organs tested (Figure 3.5D-F) of IRF1KO mice. Taken 
together, these data suggests a possible association of IRF1 in controlling iRBC 
accumulation in the brain and systemically.  
Figure 3.5 Parasite sequestrations in WT and IRF1KO mice quantified with 
bioluminescence imaging. Dynamic in vivo quantification of parasite sequestration in 
the (A) whole body and (B) head of WT (n=5) and IRF1KO (n=5) mice throughout 
the course of infection starting from 5dpi. (C-F) Ex vivo imaging of organs of 
PbAluc-infected WT (n=4) and IRF1KO (n=5) mice on 7dpi. Mice were injected with 
luciferin and iRBC accumulation was measured by bioluminescence imaging as 
described in Materials and Methods. Data are expressed on log scale as mean ± SD. 
Results are representative of combined data of two independent experiments. *p<0.05, 
**p<0.01, ***p<0.001, Unpaired Student t-test. 
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3.2.4 Absence of IRF1 does not impair antigen cross-presentation by brain 
endothelial cells  
Brain microvessels were shown to be capable of taking up parasite sequestered to 
cross-present to effector CD8+ T cells during ECM [136]. According to previous 
reports, IRF1KO mice exhibited defect in antigen presentation [279] and MHC 
expression [282, 283]. Therefore, it prompted us to investigate if absence in IRF1 
would impair antigen cross-presentation by brain microvessels. Using a brain 
microvessels cross-presentation assay, we quantify the extent of H-2D
b
-restricted 
peptide SLLNAKYL (Pb1) presentation by brain endothelial cells, which are targets 
for killing by epitope-specific CD8+ T cells in the brain. Briefly, brain microvessels 
from infected mice are isolated and incubated with reporter cell line that expresses 
lacZ upon identification of malarial epitope Pb1. After staining with X-gal, each 
reporter cell that has encountered Pb1 will turn into a blue spot. Total number of blue 
spots counted per brain represents the extent of Pb1 presentation by brain 
microvessels. We observed that brain microvessels from PbAluc-infected IRF1KO 
mice were as capable of cross-presenting the malarial parasite derived Pb1 epitope as 
the WT controls (Figure 3.6). Our data indicates that during infection, antigen 
presentation by brain microvessels is independent of IRF1 and most importantly, 
reduced parasite sequestrated in the brain of IRF1KO mice was still sufficient for 
optimal antigen cross-presentation by brain microvessels.  




Figure 3.6 Brain microvessels cross-presentation of naïve WT (n=5), PbAluc-
infected WT (n=10), naïve IRF1KO (n=4) and PbAluc-infected IRF1KO (n=9) mice 
on 8dpi when WT controls displayed ECM signs in this experiment. Data are log 
transformed and expressed as mean ± SD. Results represent data combined from two 
experiments. ***p<0.001, Unpaired Student t-test. 
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3.2.5 IRF1 is essential for leukocyte sequestration in the brain 
Accumulation of T cells, in particular CD8+ T cells, in the brain at the time of 
neurological manifestation, were shown to be the proximal cause of neuropathology 
in ECM [125]. Since previous studies have reported a T cell deficiency in IRF1KO 
mice [271, 284], we sought to determine the number of T cells sequestered in the 
brain, which is the site of pathology, during infection. At basal level, naïve IRF1KO 
mice had significantly less CD8+ T cells in the brain as compared to naïve WT mice. 
Upon infection, general increase in all T cell populations in both WT and IRF1KO 
mice was observed as compared to naïve mice. However, the number of CD4+ T cells, 
CD8+ T cells and parasite (Pb1)-specific CD8+ T cells sequestered in the brain of 
IRF1KO mice, despite higher than naïve, were significantly less than those found in 
WT mice (Figure 3.7). With this, we confirmed previous findings that absence of 
IRF1 impairs sequestration of T cells and malaria-specific CD8+ T cells in brain. 
 
 
Figure 3.7  BSL in WT and IRF1KO mice. Analysis of (A) CD4+ T cells, (B) 
CD8+ T cells and (C) Pb1-specific CD8+ T cells sequestered in the brain of naïve 
WT (n=12), PbAluc-infected (n=5), naïve IRF1KO (n=10) and PbAluc-infected 
IRF1KO (n=11) mice on 7dpi. Mice were perfused intracardially before brain was 
processed to isolate leukocytes. Data are expressed as mean ± SD and representative 
of two combined experiments. *p<0.05, **p<0.01, ***p<0.001, Unpaired Student t-
test. 
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3.2.6 Lack of IRF1 impairs activation and expansion of T cells during priming  
We speculated that decreased number of T cells in the brain of IRF1KO mice could 
be linked to impairment in T cell expansion in the spleen during priming. To assess 
this hypothesis, we first measure the levels of splenic T cell activation on 4dpi, when 
priming is known to occur. The proportion of splenic CD4+ and CD8+ T cells 
expressing an activated phenotype CD11a (also known as LFA-1 integrin ɑ-chain, 
linked to T cell adhesion/homing [285-287]) and CD69 (early marker of activation 
induced by TCR engagement [288-291]) was increased upon infection in WT and 
IRF1KO mice. However, the number of activated splenic cells in infected IRF1KO 
mice was significantly less than its WT counterparts (Figure 3.8A and B). Likewise, 
the number of activated parasite-specific CD8+ T cells in infected IRF1KO mice was 
also decreased (Figure 3.8C).  
 
Figure 3.8 T cells activation status in the spleen of WT and IRF1KO mice. 
Analysis of T cell activation markers CD11a and CD69 expressed on (A) CD4+ T 
cells, (B) CD8+ T cells and (C) parasite-specific CD8+ T cells in the spleen of naïve 
WT (n=6), PbAluc-infected WT (n=4), naïve IRF1KO (n=3) and PbAluc-infected 
IRF1KO (n=4) mice on 4dpi. Data are expressed as mean ± SD and representative of 
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Once the T cells are activated, proliferation and clonal expansion are triggered [292]. 
Since the number of activated T cells was reduced in infected IRF1KO mice, we 
investigated how this deficit in activation would cripple T cells expansion on 7dpi. 
We first observed that both naïve and infected IRF1KO mice had significantly shorter 
(in length) spleen than naïve and infected WT mice respectively (Figure 3.9). When 
the number of splenocytes was counted, infected IRF1KO mice displayed 
significantly less number of splenic CD4+ and CD8+ T cells than their WT 
counterparts (Figure 3.10A and B). However, no such difference was observed in the 
number of Pb1-specific CD8+ T cells between infected IRF1KO and WT mice 
(Figure 3.10C). Moreover, analysis on the expansion ratio showed robust 
proliferation of Pb1-specific CD8+ T cells in the absence of IRF1 (Figure 3.10D). 
Overall, these data clearly show that IRF1 is required for optimal overall T cells 
activation and expansion during malaria infection. Despite that, absence of IRF1 does 
not abrogate expansion of malaria-specific CD8+ T cells.  
 
Figure 3.9 Size of spleen from WT and IRF1KO mice. Size of the spleen (cm) 
of naïve WT (n=6), PbAluc-infected WT (n=18), naïve IRF1KO (n=9) and PbAluc-
infected IRF1KO (n=21) mice on 7dpi. Data are expressed as mean ± SD and 
representative of two combined experiments. **p<0.01, ***p<0.001, Unpaired 
Student t-test.  
 




Figure 3.10 Splenic T cell populations in WT and IRF1KO mice. Analysis of 
splenic (A) CD4+ T cells, (B) CD8+ T cells and (C) parasite-specific CD8+ T cells in 
naïve WT (n=12), PbAluc-infected WT (n=7), naïve IRF1KO (n=10) and PbAluc-
infected IRF1KO (n=11) mice on 7dpi. (D) Expansion ratio of Pb1-specific CD8+ T 
cells in the spleen of WT (n=7) and IRF1KO (n=11) mice on 7dpi. Data are expressed 
as mean ± SD and representative of two combined experiments. *p<0.05, **p<0.01, 
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3.2.7 IRF1 deficiency decreases number of CXCR3-expressing T cells in the 
spleen 
Since the expansion of Pb1-specific CD8+ T cells was not affected in the spleen of 
IRF1KO mice, yet there was significant decrease of this population sequestered in the 
brain, we hypothesized that the migratory signal required to induce T cell migration 
from the spleen to the brain was defective. The hypothesis was supported by the fact 
that infection decreased the number of splenic CD8+ T cells in WT mice but not in 
IRF1KO mice (Figure 3.10B). This suggests that during infection, CD8+ T cells in 
the spleen of IRF1KO mice were not able to migrate out and therefore accumulated in 
the spleen. To investigate the migratory capacity, we first examine production of 
chemokine IP-10. IP-10 was previously shown to be crucial in promoting T cells 
migration during ECM [293] and its absence can induce either partial [171] or 
complete [293, 294] protection from ECM. Serum concentration of IP-10 was 
measured and no significant difference was observed between infected WT and 
IRF1KO mice (Figure 3.11).  
 
Figure 3.11 Level of IP-10 in the serum of PbAluc-infected WT (n=4) and 
IRF1KO (n=4) mice on 7dpi. Data are expressed as mean ± SD and representative of 
a single experiment.  
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The receptor for IP-10 is chemokine receptor CXCR3. Analysis on the brain 
infiltrating leukocytes in ECM-susceptible mice revealed that approximately 90% of 
the leukocytes expressed CXCR3 as compared to naïve or ECM-resistant mice [142, 
144, 170]. In addition, mice deficient of CXCR3 displayed partial protection from 
ECM due to reduced CD8+ T cells migrated into the brain. Therefore, we decided to 
investigate whether the decreased number of T cells sequestered in the brain of 
IRF1KO mice correlated with a reduction in CXCR3 expressing T cells in the spleen. 
Indeed, our results showed that the number and percentage of CXCR3-expressing 
CD4+, CD8+, and parasite-specific CD8+ T cells was significantly less in naïve and 
infected IRF1KO mice as compared to their counterparts (Figure 3.12). Taken 
together, these results confirmed our previous hypothesis that in the absence of IRF1, 
the impairment in the migration of activated T cells from the spleen to the brain is 
due to reduced CXCR3-expressing T cells.   
 
Figure 3.12 Chemokine expression on splenic T cells in WT and IRF1KO mice. 
Analysis of chemokine receptor CXCR3 expressed on (A) CD4+ T cells, (B) CD8+ T 
cells and (C) parasite-specific CD8+ T cells in the spleen of naïve WT (n=3), PbAluc-
infected WT (n=9), naïve IRF1KO (n=5) and PbAluc-infected IRF1KO (n=6) mice 
on 7dpi. Percentage of cells expressing CXCR3 on (D) CD4+ T cells, (E) CD8+ T 
cells and (F) parasite-specific CD8+ T cells in the spleen of naïve WT (n=3), PbAluc-
infected WT (n=9), naïve IRF1KO (n=5) and PbAluc-infected IRF1KO (n=6) on 7dpi. 
Data are expressed as mean ± SD and representative of a single experiment. *p<0.05, 
**p<0.01, ***p<0.001, Unpaired Student t-test. 
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3.2.8 Lack of IRF1 alters the number of IFN-γ-secreting cells and reduces IFN-γ 
production  
CXCR3 is preferentially expressed on Th1-type CD4+ T cells and effector CD8+ T 
cells [295, 296], and when up-regulated, triggers the induction of these cells [297], 
particularly IFN-γ-producing Th1 cells [298, 299]. Since we have demonstrated that 
in the absence of IRF1, there is marked reduction in number of CXCR3-expressing T 
cells on 7dpi, we wondered if this decrease would affect induction of IFN-γ-
producing cells. Splenocytes were collected on 7dpi and analysed by intracellular 
cytokine staining. The proportion of splenic IFN-γ+CD4+ and CD8+ T cells was 
increased in WT and IRF1KO mice upon infection. However, the increase observed 
in infected IRF1KO mice was not as high as the one observed in infected WT mice 
(Figure 3.13A and B). Next, we decided to see if the decreased number of IFN-γ-
producing cells in IRF1KO mice affected IFN-γ production. Serum concentration of 
IFN-γ in IRF1KO mice was significantly lower as compared to WT mice (Figure 
3.13C). This data corroborates with previous studies which also demonstrated that 
absence of IRF1 downregulated level of IFN-γ production [113, 257], leading to a 
less pro-inflammatory Th1 response [277, 284].        
 




Figure 3.13 IFN-γ-secreting cells and production level in WT and IRF1KO mice. 
Analysis of IFN-γ-secreting (A) CD4+ T cells and (B) CD8+ T cells in the spleen of 
naïve WT (n=3), PbAluc-infected WT (n=9), naïve IRF1KO (n=5) and PbAluc-
infected IRF1KO (n=6) mice on 7dpi. (C) Level of serum IFN-γ in naïve WT (n=4), 
PbAluc-infected WT (n=5), naïve IRF1KO (n=3) and PbAluc-infected IRF1KO (n=8) 
mice on 7dpi. Data are expressed as mean ± SD and representative of two combined 
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3.2.9 Altered IFN-γ/IL-10 ratio defines susceptibility to ECM in IRF1KO mice 
Interleukin-10 (IL-10) is a pleiotropic anti-inflammatory cytokine known to cause a 
Th1/Th2 imbalance by promoting the development of Th2 response, through 
inhibition of IFN-γ production by T cells via suppression of IL-12 synthesis [300, 
301]. Recently, it has emerged as a key immunoregulator as it ameliorates excessive 
Th1 and CD8+ T cells response that usually leads to immunopathology during 
infections such as Trypanosoma spp. [302-304] and Plasmodium spp. [305-308]. In 
rodent malaria model, high levels of constitutive IL-10 mRNA was detected in the 
spleen and brain of resistant mice [305, 309]. The in vivo neutralization of 
endogenous IL-10 was shown to lead to ECM development [305]. Kossodo and 
colleagues suggested that protective role of IL-10 in ECM development is mediated 
through suppression of IFN-γ production by splenocytes [305]. Since we did observe 
a decrease in the serum level of IFN-γ as well as in the number of splenic IFN-γ-
producing cells in IRF1KO mice, we postulated that IL-10 is elevated in these mice 
on 7dpi. To our surprise, no significant difference in serum concentration of IL-10 
(Figure 3.14A) and splenic IL-10 mRNA expression (Figure 3.14B) was observed 
between infected groups. This suggests that the reduced IFN-γ activity is not a result 
of elevated IL-10 secretion.  
 
Imbalance between pro- and anti-inflammatory immune response was shown to 
induce immune-mediated pathology [309]. Therefore, we calculated the ratio of IFN-
γ to IL-10 and observed that it was reduced in IRF1KO mice as compared to WT 
mice (Figure 3.14C).  Our data suggested that the decrease in pro-inflammatory 
immune response induced during infection in IRF1KO mice could be the reason for 
protection from ECM death.  




Figure 3.14 (A) Level of serum IL-10 (pg/ml) in naïve WT (n=4), PbAluc-
infected WT (n=12), naïve IRF1KO (n=3) and PbAluc-infected IRF1KO (n=15) mice 
on 7 dpi. (B) Quantitative real-time PCR of IL-10 expression in the spleen of PbAluc-
infected WT (n=5) and IRF1KO (n=4) mice on 7dpi, normalized to naïve mice. Data 
are expressed as mean ± SD. (C) Ratio of serum IFN-γ/IL-10 of infected WT and 
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To confirm that a precise Th1/Th2 response is essential for ECM protection, and IL-
10 is an important anti-inflammatory cytokine needed to maintain the equilibrium for 
ECM protection in IRF1KO mice, we treated the mice with a blocking monoclonal 
antibody specific for IL-10 receptor (IL-10R). Both ɑ-IL-10R treated WT and 
IRF1KO mice displayed neurological signs and succumbed to ECM on 7 and 8 dpi 
(Figure 3.15A) despite parasitemia of treated IRF1KO mice being significantly higher 
than treated WT mice (Figure 3.15B). We can conclude that in the absence of IRF1, 
the control of parasitemia in IRF1KO mice happens independently of IL-10 signalling, 
and the blockade of IL-10R reverse ECM protection.  
 
Figure 3.15 (A) Survival (%) and (B) parasitemia (%) of PbAluc-infected WT 
(n=5) and IRF1KO (n=4) mice upon treatment with IL-10R blocking antibody. Data 
















In this study, we demonstrated that immune response induced by IRF1 is crucial for 
the control of parasitemia during infection, and its absence confers protection from 
ECM death via a dampened pro-inflammatory T cell response determined by the IFN-
γ/IL-10 ratio. We showed that an abrogated overwhelming T cell response in the 
spleen and reduced number of CXCR3-expressing T cells infiltrating the brain limited 
damage to the BBB.    
 
Although IRF1 deficiency conferred protection against ECM death to the mice, it did 
not impede the development of neurological signs during infection (Figure 3.1B). 
Further examinations of brain section revealed the presence of injuries, albeit reduced, 
in infected IRF1KO mice as compared to WT mice (Figure 3.2). We deduced that the 
degree of damage is the key determinant of survival outcome. A study conducted by 
another group proposed that at early time-points, widespread BBB damage can be 
regulated, reversible and preventable [128]. This concept fits into our findings and it 
does explain the distinct survival outcome. Here, we proposed that the form of injury 
in IRF1KO mice is possibly a reversible damage which is sufficient to evoke 
neurological signs but not extensively enough to cause ECM death.      
 
Previous studies emphasized the importance of dual presence of parasite-specific 
CD8+ T cells and high parasite biomass in the brain for cerebral disease to occur [136, 
147, 157, 310]. IRF1 is essential for CD8+ T cells development because in its 
absence, the negative and positive selection in the thymus was shown to be impaired 
[271, 278, 279]. Our results go in agreement with this finding as we did observe a 
defect in the number of splenic CD8+ T cells in naive IRF1KO mice, which remained 
significantly lower even upon infection (Figure 3.10C). Interestingly, even though 
there was no difference in the number of parasite-specific CD8+ T cells present in the 
spleen of both infected groups (Figure 3.10D), the expansion ratio indicated that in 
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the absence of IRF1, Pb1-specific CD8+ T cells have an improved proliferation 
capacity (Figure 3.10E). This result is in line with previous study in West Nile Virus 
(WNV) infection, whereby naïve IRF1KO mice also possessed fewer CD8+ T cells 
but were able to expand their pool of WNV-specific cytolytic CD8+ T cells. This 
capacity to expand specific CD8+ T cells was attributed to the extrinsic environment 
coupled with intrinsic capacity to proliferate rapidly in the absence of IRF1 [311]. 
Adoptive transfer study and ex vivo proliferation assay will be performed in order to 
verify the applicability of this concept to our model.   
 
Despite the exceptional capacity to expand and proliferate as many Pb1-specific 
CD8+ T cells in the spleen as WT mice, IRF1KO mice had lower number of malaria 
specific-CD8+ T cells in the brain (Figure 3.7D). We hypothesized that the migration 
process from the site of expansion (spleen) to the site of sequestration (brain) is 
defective. Analysis on the number and percentage of CXCR3-expressing T cells 
population, including Pb1-specific CD8+ T cells, showed a decrease in infected 
IRF1KO mice, supporting the hypothesis of defective T cells trafficking. Here, we 
also showed that the cause of reduced CXCR3-expressing cells is due to an impaired 
Th1 differentiation in IRF1KO mice, as characterized by a decrease in the number of 
IFN-γ-producing cells (Figure 3.13). It is known that IFN-γ represses Interleukin-4 
(IL-4) gene, a Th2 cytokine, to promote Th1 differentiation in IRF1-dependent 
manner [275]. This means that in the absence of IRF1, a pre-dominant Th2 
differentiation is induced as a result of impaired IL-4 repression, and this supports our 
observation that during infection in IRF1KO mice, a weakened Th1 response is 
induced. 
 
Interleukin-12 (IL-12) is an important cytokine involved in the differentiation of 
naïve T cells into Th1 cells, stimulates the production of IFN-γ, and reduces 
suppression of IFN-γ by IL-4 [312]. In the absence of IRF1, production of IL-12 is 
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impaired and responsiveness to the cytokine also decreases, mitigating Th1 response 
[277]. A study by another group showed that this phenomenon observed in IRF1KO 
mice is reversible when 100ug recombinant IL-12 (rIL-12) was administered as it 
upregulated IFN-γ mRNA expression and its production, thus promoting a Th1 
response [257]. Following a similar approach, we tried to modify the weakened Th1 
differentiation by blocking signalling pathway induced by IL-10. We showed that 
blockage of IL-10R by a monoclonal antibody specific for IL-10R was able to reverse 
ECM protection in IRF1KO mice (Figure 3.15A). Taken together, we and others 
proved that the fine balance of the Th1/Th2 (IL-12/IL-4) or pro-/anti-inflammatory 
(IFN-γ/IL-10) is imperative in the outcome of ECM development.       
 
Peripheral parasitemia is mainly regulated by IFN-γ-producing CD4+ T cells [118, 
313, 314]. In chronic hepatitis C virus infection model, the blockade of IL-10R 
altered the inflammatory response towards a type 1-antiviral T cell reactivity, by 
increasing the secretion of IFN-γ and the number of specific IFN-γ-producing T cells 
[315]. Therefore, we were expecting to see an improved control in circulating 
parasites in ɑ-IL10R-treated IRF1KO mice, which was not the case (Figure 3.15B). 
Hence, we deduced that in the absence of IRF1, an immune response independent of 
IL-10 signalling remain defective in the control of parasitemia. We did not perform 
further studies to confirm if increased IFN-γ production occurred. In addition, based 
on the observation of reduced brain-sequestered leukocyte (Figure 3.7) and parasite 
sequestration in all organs studied (Figure 3.5C-F), it is possible that absence of IRF1 
impairs cytoadherence of cells in the brain and as a result, it increases the proportion 
of parasites circulating in the bloodstream.    
 
In summary, we have revealed that IRF1 signalling determines susceptibility to ECM 
through the modulation of IFN-γ/IL-10 ratio and regulates production of CXCR3-
expressing T cells in the spleen. Moreover, using a blocking monoclonal antibody for 
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IL-10R, we were able to manipulate the cytokine milieu and reverse ECM resistant 
phenotype observed in IRF1KO mice.  






























CHAPTER 4  
INTERFERON REGULATORY 7 IS NOT CRUCIAL IN EXPERIMENTAL 
CEREBRAL MALARIA BUT CONTROLS PARASITE GROWTH 
 
4.1 Introduction 
IFN-I is a family of interferon proteins consisting of two main groups, IFN-ɑ and 
IFN-β. Production of both cytokines is generated through a biphasic mechanism. 
Recognition of PAMPs and DAMPs will first lead to a downstream phosphorylation 
of the inactive interferon regulatory factor 3 (IRF3), translocating it from the cytosol 
into the nucleus. This activated form of IRF3 mediates the production of IFN-β, IFN-
ɑ4 and IRF7. Subsequently, signalling of IFN-β through IFNAR activates IRF7 and 
induces other IFN-ɑ and interferon-stimulated genes (ISGs). 
 
This chapter will focus on the role of IRF7 in ECM pathogenesis. IRF7 is expressed 
at low level in the cytosol of several cells, and its expression is tightly regulated by 
positive feedback loop of IFN-β. Besides mediating IFN-ɑ production, IRF7 was 
shown to contribute to CD4+ Th-cell responses in Leishemania by balancing the 
production of IFN-γ and IL-10 [316]. While in acute lymphocytic choriomeningitis 
virus infection (LCMV), IRF7 does not control CD4+ T cells responses, there are 
evidences showing that it regulates the expansion of virus-specific CD8+ T cells 
[317]. In the mouse model for multiple sclerosis, termed experimental autoimmune 
encephalomyelitis (EAE), deficiency in IRF7 promoted disease severity due to 
marked increase in leukocyte infiltration to the CNS. This increase was due to 
elevated expression of chemokines CCL2 and CXCL10 [318], suggesting that 
presence of IRF7 suppresses chemokine production and is crucial in driving T cell-
mediated immune response.    
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Analysis in the sera of Thai patients infected with malaria revealed presence of IFN-ɑ, 
which is solely dependent on IRF7, precedes the release of IFN-γ in the circulation, 
suggesting that IFN-ɑ may modulate immune response during malaria infection, 
including those suffered from CM [77]. At the same time, microarray analysis of 
brain from infected mice detected significantly higher IRF7 in ECM-susceptible mice 
as compared to ECM-resistant [103] and naïve control mice [108]. Taken together, 
these results seem to imply that IRF7 might be playing a role in ECM pathogenesis.  
 
In collaboration with Ashraful Haque and Chelsea Edwards (Queensland Institute for 
Medical Research, Brisbane, Australia), the study on the role of IRF7 in ECM 






















4.2.1 IFN-I signalling is crucial in ECM development 
Since production of IFN-I is regulated by IRF3 and IRF7; we were interested in the 
importance of IFN-I signalling in ECM development. Previous studies have 
demonstrated that absence of IFN-I signalling in IFNARKO mice infected with PbA-
GFP either delayed or fully protected the mice against ECM death [118, 119, 123]. In 
order to confirm that IFNAR plays an important role in ECM development, 
IFNARKO mice were infected with PbAluc and monitored for ECM susceptibility. 
While 90% of infected WT mice died of ECM on 8 and 9 dpi, only 10% of IFNAR-
KO mice were susceptible to ECM death (Figure 4.1). This ECM-resistant phenotype 
observed in IFNAR-KO mice corroborated with previous data and suggests that IFN-I 
signalling is essential for ECM development regardless of parasite clone. 
 
Figure 4.1 Survival of WT (n=12) and IFNARKO (n=8) mice infected with 
PbAluc. The shaded area represents the days that WT mice displayed neurological 
symptoms. #p<0.05, log-rank test. Result is representative of combined data of two 
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4.2.2 IRF7 has no important role in the development of ECM 
Since our data demonstrated IFN-I signalling is crucial in ECM development and 
IRF7 is one of the transcription factors necessary in IFN-I signalling, we attempted to 
identify and understand the exact function of IRF7 in ECM pathogenesis. WT and 
mice deficient of IRF7 (IRF7KO) were infected with PbAluc intraperitoneally and 
monitored for neurological signs and survival. Between 7-14 dpi, all infected WT and 
IRF7KO displayed neurological signs and eventually died (Figure 4.2). No difference 
in survival was observed between the two groups suggesting that deficiency in IRF7 
does not alter ECM susceptibility.  
 
Figure 4.2 Survival of WT (n=16) and IRF7KO (n=24) mice infected with 
PbAluc. The shaded area represents the days that WT mice displayed neurological 
symptoms. Result is representative of three experiments performed by Gun. 
 
Mice suffering from ECM have been reported to display multiple focal haemorrhages 
in the brain sections [148, 320]. Since both WT and IRF7KO mice were susceptible 
to ECM, we quantify the number of haemorrhages spots in the brain of both groups 
through H&E staining. Histopathological analysis of brain sections displayed 
presence of haemorrhages in both infected WT and IRF7KO mice (Figure 4.3A - 
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results from Edwards et al.,) with enumeration of cerebellar haemorrhages in both 
groups significantly higher as compared to naïve WT mice. Although brain sections 
of IRF7KO mice appeared to exhibit less petechial haemorrhages, it is not statistically 
significant as compared to WT mice (Figure 4.3B). Next, we performed Evans Blue 
extravasation assay to assess the extent of damage in the BBB. The extent of the dye 
leakage was similar in both infected WT and IRF7KO (Figure 4.3D). Representative 
images of brains stained with Evans Blue from naïve WT, infected WT, naïve 
IRF7KO and infected IRF7KO mice are depicted in Figure 4.3C. Taking all these 
data together, it can be suggested that absence of IRF7 does not seem to prevent brain 
pathology, as haemorrhages and vascular damage are similar to WT mice 
 
Figure 4.3 Assessment of BBB integrity in WT and IRF7KO mice. (A) H&E 
histopathology of brain and (B) enumeration of cerebellar haemorrhage of naïve WT 
(n=6), PbAluc-infected WT (n=5) and IRF7KO (n=5) mice (10
5 
fresh iRBC i.p.) on 7 
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dpi. Histology was performed by Edwards (Chelsea L. Edwards) (C) Qualitative and 
(D) quantitative brain capillary permeability assessed after i.v. injection of Evans 
Blue dye in naïve WT (n=5), PbAluc-infected WT (n=6), naïve IRF7KO (n=4) and 
PbAluc-infected IRF7KO (n=7) mice on 7dpi. Data are expressed as mean ± SD and 
representative of a single experiment performed by Gun. *p<0.05, **p<0.01, 
***p<0.001, Unpaired Student t-test.  
 
4.2.3 Absence of IRF7 reduces leukocyte sequestration in the brain but does not 
impair expansion of splenic CD8+ T cells   
CD8+ T cell has been repeatedly demonstrated to be the main effector cells directly 
inducing damage to the integrity of BBB [100, 124, 143, 144] and increased in ECM-
susceptible mice as compared to resistant mice [124, 145]. Recently, parasite-specific 
CD8+ T cell, that recognize the parasite epitope Pb1, was shown to induce BBB 
damage during ECM pathogenesis [136]. Although IRF7KO displayed no changes in 
susceptibility to ECM, we further our studies on the characterization of leukocyte 
profile because studies in other disease models suggested its role in regulating T cell-
mediated immune response [316-318]. Upon infection, increase in total leukocytes, 
CD4+, CD8+ and parasite-specific CD8+ T cells in both WT and IRF7KO mice was 
observed on 7dpi. Comparison between infected WT and IRF7KO mice showed a 
significant decrease in total leukocytes, CD8+ T cells and parasite-specific CD8+ T 
cells in brain of infected IRF7KO mice (Figure 4.4). No significant difference in the 
number of CD4+ T cells was found in both groups (Figure 4.4B). It is important to 
take note that, despite less leukocytes sequestrated in the brain of IRF7KO mice; it 
does not mitigate ECM development in these mice.      




Figure 4.4 BSL in WT and IRF7KO mice. Analysis of total leukocytes, CD4+ T 
cells, CD8+ T cell and Pb1-specific CD8+ T cell sequestered in the brain of 
intracardially perfused naïve WT (n=5), PbAluc-infected WT (n=9), naïve IRF7KO 
(n=5) and PbAluc-infected IRF7KO (n=14) mice on 7dpi. Data are expressed as mean 
± SD and representative of combined data of two experiments performed by Gun. 
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Since IRF7KO mice had significantly less CD8+ and parasite-specific CD8+ T cells 
sequestered in the brain as compared to WT mice, we wondered if absence in IRF7 
lead to such a decrease in leukocytes sequestration due to an inadequate expansion of 
this T cell population in the spleen. Likewise to what was found in the brain, upon 
infection with PbAluc parasite, CD8+ and parasite-specific CD8+ T cells were 
increased in WT and IRF7KO mice on 7dpi (Figure 4.5A). Interestingly, the number 
of parasite-specific CD8+ T cells was significantly higher in infected IRF7KO as 
compared to WT mice (Figure 4.5B). This suggests that absence of IRF7 promotes 
expansion of Pb1-specific CD8+ T cell population.  
 
Figure 4.5 Splenic T cell populations in WT and IRF7KO mice Analysis of 
splenic CD8+ T cells and parasite-specific CD8+ T cells in naïve WT (n=5), PbAluc-
infected WT (n=9), naïve IRF7KO (n=5) and PbAluc-infected IRF7KO (n=12) mice 
on 7dpi. Data are expressed as mean ± SD and representative of combined data of two 
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4.2.4 Lack of IRF7 does not impair antigen cross-presentation by brain 
microvessels and parasite sequestration in the brain  
It was previously demonstrated that a specific population of CD8+ T cells that 
migrated into the brain is able to recognize parasite epitope presented on MHC class I 
molecules of brain microvessels, and to initiate targeted killing of these epitope-
presenting endothelial cells [136]. To verify if IRF7 is involved in the regulation 
antigen presentation by brain endothelial cells, brain microvessels cross-presentation 
assay was performed. As depicted in Figure 4.6, no difference in antigen cross-
presentation was observed between infected WT and IRF7KO mice, indicating 
antigen presentation is not impaired in the absence of IRF7.   
 
Figure 4.6 Brain microvessels cross-presentation of naïve WT (n=5), PbAluc-
infected WT (n=5), naïve IRF7KO (n=3) and PbAluc-infected IRF7KO (n=8) mice 
on 8dpi. Data are log transformed and expressed as mean ± SD. ***p<0.001, 
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According to Howland et al., the local accumulation of parasite in the brain plays an 
important role in controlling antigen cross-presentation by brain microvessels [136]. 
Therefore, we wondered whether lack of IRF7 would affect the control of parasite 
sequestered in the brain. Ex vivo imaging in perfused brains of infected mice showed 
no significant difference in bioluminescence signal between infected WT and 
IRF7KO on 7dpi (Figure 4.7A). However, dynamic in vivo imaging of the head of 
infected mice showed that the bioluminescence signal was decreased in the head of 
infected IRF7KO mice on 5, 7 and 8 dpi compared to infected WT mice (Figure 
4.7B), suggesting that less parasites biomass in the head.  
 
Figure 4.7 Parasite sequestrations in WT and IRF7KO mice quantified with 
bioluminescence imaging. (A) Ex vivo quantification by bioluminescence imaging of 
parasite iRBC in the brain of PbAluc-infected WT (n=9) and IRF7KO (n=7) mice on 
7dpi. (B) In vivo bioluminescence imaging of iRBC accumulated in the head of WT 
(n=5) and IRF7KO (n=5) mice. Data are expressed as mean ± SD and representative 
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4.2.5 IRF7 impedes the control of circulating parasites during infection 
In vivo imaging of the head takes into account both parasite sequestered in the brain 
and circulating parasites in the brain capillaries, Due to the discrepancy found 
between ex vivo and in vivo imaging, we sought to measure the peripheral parasitemia 
of WT and IRF7KO mice during the course of infection. We observed that indeed 
infected IRF7KO mice had significantly lower parasitemia than WT mice on 6, 7, 8 
dpi (Figure 4.8), explaining the decrease observed previously in the in vivo 
bioluminescence in the head of infected IRF7KO mice. This data suggests that 
although the lack of IRF7 does not affect the amount of parasite sequestered in the 
brain, it promotes the control of circulating parasites.           
 
Figure 4.8 Parasitemia (%) of WT (n=5) and IRF7KO (n=5) mice infected with 
PbAluc. Data are expressed as mean ± SD and representative of a single experiment 






 Chapter 4 Interferon Regulatory Factor 7 
84 
 
4.2.6 IRF7 suppresses early splenic Th1 response and regulates IFN-ɑ production  
The control of parasitemia was previously shown to be dependent on IFN-γ-
producing Th1 subsets [314], which is regulated by transcription factor T-bet [321-
323]. In order to determine whether the parasite control observed in IRF7KO mice 
was due to a more powerful Th1 immune response, we measured the expression of T-
bet and IFN-γ by splenic CD4+ T cells on 4dpi because this is the time that priming 
was shown to happen. Figure 4.9 shows that infected IRF7KO mice had significant 
increase in the number of IFN-γ+ T-bet+ CD4+ T cells as compared to WT mice 
(data from Edwards et al.,), indicating that IRF7 is suppressing early splenic Th1 
response during infection.  
 
Figure 4.9 T-bet and IFN-γ expressing T cells in the spleen of WT and IRF7KO 
mice. Analysis of splenic CD4+ T cells co-expressing T-bet and IFN-γ in naïve WT 
(n=3), PbAluc-infected WT (n=9) and PbAluc-infected IRF7KO (n=5) mice on 7dpi 
(10
5 
fresh iRBC i.p.). Data are expressed as mean ± SD and representative of two 
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IFN-I signalling was shown to suppress T-bet+ CD4+ T cells-derived IFN-γ 
production during PbA infection [118]. Since IRF7 regulates IFN-ɑ production which 
is essential for IFN-I signalling, we measured the level of IFN-ɑ production in both 
WT and IRF7KO on 4dpi. While substantial IFN-ɑ level was detected in WT mice, 
the amount of IFN-ɑ in the serum of IRF7KO was undetectable (Figure 4.10 – data 
from Edwards et al., 2014). Taken together, systemic IFN-ɑ production is showed to 
be IRF7-dependent and its presence cripples Th1 response in PbA infection.  
 
Figure 4.10 Serum level of IFN-ɑ (pg/ml) in naïve WT (n=3), PbAluc-infected 
WT (n=5) and PbAluc-infected IRF7KO (n=5) mice on 4dpi (10
5 
fresh iRBC i.p.). 
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4.2.7 IRF7 regulates Th1 response 
In order to confirm that the above phenotype observed was not linked to 
developmental defects in IRF7KO mice, bone marrow reconstitution was performed. 
Irradiated WT mice were reconstituted with transplanted bone marrow cells from 
either WT or IRF7KO mice. Consistent with the data observed earlier (Figure 4.9), 
the number of IFN-γ+ CD4+ T cells in WT mice reconstituted with donor cells from 
IRF7KO mice was significantly higher than those reconstituted with donor cells from 
WT mice (Figure 4.11 – data from Edwards et al.,). This data clearly confirmed that 
the hematopoietic cells in IRF7KO mice are the ones responsible for the increase in 
numbers of IFN-γ+ CD4+ T cells and subsequently a stronger Th1 response.  
 
Figure 4.11 Splenic CD4+ T cells expressing IFN-γ in naïve WT or infected bone 
marrow chimeric WT mice on 4dpi. WT mice were lethally irradiated and engrafted 
with bone marrow cells from either WT (WT > WT) or IRF7KO (IRF7 > WT) mice. 
12 weeks later, WT > WT (n=5) and IRF7 > WT (n=6) mice were intraperitoneally 
infected with 10
5 
fresh iRBC and sacrificed 4 days later to obtain splenocytes. Data 
are expressed as mean ± SD and representative of two independent experiments 











In this chapter, we have firstly confirmed previous data by other groups that IFN –I 
signalling is essential in ECM development (Figure 4.1). Then, we demonstrated that 
in the absence of IRF7, mice remain susceptible to ECM (Figure 4.2), however, they 
display a better control in peripheral parasitemia (Figure 4.8). This control is 
mediated through the increase in splenic IFN-γ producing T-bet+ CD4+ T cells due to 
a lack of IFN-ɑ production.  
 
Histopathological examinations and Evans Blue extravasation assay showed that the 
extent of BBB damage in infected IRF7KO mice was similar to WT mice (Figure 4.3). 
Although parasite load (Figure 4.7A) and antigen cross-presentation (Figure 4.6) in 
the brain of infected IRF7KO mice remained unchanged, a decrease in CD8+ T cells 
and parasite-specific CD8+ T cells as compared to WT mice was observed (Figure 
4.4). We hypothesized that this decrease could be due to a deficit in T cells priming in 
the spleen. However, we found that not only the T cells were able to expand normally 
in the spleen of IRF7KO mice (Figure 4.5), but also have significantly more Pb1-
specific CD8+ T cells compared to WT mice (Figure 4.5B). This excludes the 
hypothesis that the reduction observed in brain-sequestered Pb1-specific CD8+ T 
cells was due to lack of T cells in the spleen, and give rise to the possibility that the 
problem could be linked to impaired T cell trafficking. Involvement of IRF7 in T cell 
trafficking has thus far been controversial. While in EAE disease model, IRF7 
deficiency was shown to promote macrophage and T cells infiltration into the CNS 
through increased in expression of chemokines such as CCL2 and CXCL10 [318], in 
other models, IRF7 was shown to promotes T cell trafficking through IFN-I [324, 
325]. Also, another study demonstrated that dendritic cells upon stimulation with 
Mycobacterium tuberculosis, produce IFN-I that leads to the synthesis of CXCL10, 
but not CXCL9 [324]. CXCL10 is a crucial chemokine shown to be involved in T cell 
trafficking during ECM development [171, 293, 294]. For this reason, it can be 
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speculated that during PbAluc infection, the lack of IFN-ɑ production in IRF7KO 
mice impedes normal IFN-I signalling, interfering CXCL10 production, and thereby 
impairing trafficking of T cells to the brain. Measurement of serum level of 
chemokines during infection is needed to confirm this hypothesis. Importantly, it 
should be noted that even though the number of Pb1-specific CD8+ T cells 
sequestered in the brain was reduced, it was sufficient to induce damage in the BBB 
of infected IRF7KO mice, and eventually ECM death.  
 
Previous studies have shown that treatment with repeated doses of recombinant 
human IFN-ɑ significantly improves outcome of ECM, as a result of marked 
reduction in parasite load sequestered in the brain due to lower expression of ICAM-1 
on endothelial cells [245]. In our model, the reduced level of IFN-ɑ found in the sera 
of infected IRF7KO mice did not correlate with ECM protection. Moreover, the 
amount of parasite accumulated in the brain was similar to WT mice (Figure 4.7A), 
indicating that the absence of IFN-ɑ in infected IRF7KO mice did not affect ICAM-1 
expression in the brain. Perhaps, the timing when IFN-ɑ is produced during infection 
plays a major role.  
 
The same group also showed that when PbA infected mice are treated with IFN-ɑ, 
decrease in splenic T cells number is observed as compared to untreated WT mice 
[245]. Contradicting with this observation, our infected IRF7KO mice had higher 
number of CD8+ T cells in the spleen (Figure 4.5), suggesting that presence of IFN-ɑ 
limits expansion of splenic T cells during PbAluc infection in our model. This idea 
conflicts with the prevailing concept that IRF7 and IFN-I signalling promotes T cells 
expansion during various infection models [326-329]. Nevertheless, further studies 
have to be performed in order to define the unique function of IRF7 and IFN-ɑ in the 
suppressing mechanism of T cell expansion in the spleen during PbAluc infection.          
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We have also demonstrated that in the absence of IRF7, the control of peripheral 
parasitemia on 6, 7, 8 dpi was regulated by the increased number of IFN-producing 
T-bet CD4+ T cells. This corroborates with previous study done by Haque et al., who 
showed that the IFN-I signalling in CD8- dendritic cells suppresses priming of strong 
Th1 response by CD4+ T cell [164], thereby contributing to poor control of parasite 
during infection [118]. On the other hand, Haque and our data contradict with other 
studies which have shown that higher level of IFN-γ produced by CD8+, but not 
CD4+, T cells inhibits blood stage parasites [245]. Nevertheless, all studies have a 
common finding which is the importance of IFN-γ in governing the control of 
peripheral parasitemia. In a model of mycobacterial infection, upon antigen 
stimulation, CD4+ T cells were shown to release more IFN-γ than CD8+ T cells at 
various time points [330], suggesting that during infection, the capacity of different T 
cell population to secrete IFN-γ is induced differently.  
 
Up to now, all evidences supporting the importance of IFN-I in ECM development 
stem from studies in IFNAR-KO mice [118, 119, 123]. IFN-I signalling requires IFN-
β and IFN-ɑ which are regulated by IRF3 and IRF7 respectively. Here we have 
shown that IRF7KO mice are still susceptible to ECM despite an abolished IFN-ɑ 
production, leading to the conclusion that in IFNAR-KO mice, ECM resistance 
occurs independently of IRF7 and IFN-ɑ. Therefore, we speculate that in IFNAR-KO 
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CHAPTER 5  
INTERFERON REGULATORY 3 REGULATES INTERFERONS WHICH 




In the previous chapter, we demonstrated that IRF7 is not essential for ECM death. 
Interferon Regulatory Factor 3 (IRF3) is another master regulator involved in the 
production of IFN-I. While IRF7 is responsible for the secondary phase of IFN-I 
production, IRF3 is activated earlier upon recognition of foreign pathogens which 
leads to primary production of IFN-I [331]. At basal level in most cells types, 
abundant IRF3 is exclusively localized in the cytoplasm and remains inactivated. 
Recognition of foreign PAMPs or DAMPs by PRRs activates downstream signalling 
molecules to induce IRF3 dimerization and entry into the nucleus [259]. Activated 
IRF3 binds to the gene promoter site to induce transcription of IFN-ɑ4, IFN-β, IRF7 
and some cytokines [Sakaguchi-2003].  
 
IRF3 is essential for immune response against viral infection such as 
encephalomyocarditis virus (EMCV). Mice deficient of IRF3 (IRF3KO) display no 
overt abnormality; yet infection led to higher susceptibility as compared to WT 
controls. This inability to cope with the viral infection was due to a compromised 
IFN-I production [331]. Besides, IRF3 in the CNS is shown to be important in 
modulating neuroinflammation. Through in vitro study of primary human astrocyte 
and primary human fetal microglia, it revealed that overexpression of IRF3 changes 
the cytokine profile in response to various inflammatory stimuli, like LPS, poly(I:C), 
IL-1β/IFN-γ by switching the activation phenotype from proinflammatory to anti-
inflammatory [332]. IRF3 suppresses expression of proinflammatory genes and at the 
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same time upregulates expression of anti-inflammatory genes such as IRF7 [332, 
333].  
  
Since IRF3 is the main transcription factor that kick start the whole process of IFN-I 
signalling, and we have shown that IFN-I signalling, but not IRF7, is crucial in ECM 
development, we seek to understand how absence of IRF3 will affect this pathology 


























5.2.1 IRF3 is essential for the development of ECM 
To assess the importance of IRF3 in ECM development, WT and IRF3KO mice were 
infected with PbAluc intraperitoneally and monitored for neurological signs and 
survival. Between 7-10 dpi, all infected WT developed ECM signs and died. On the 
other hand, none of the infected IRF3KO mice displayed any neurological signs and 
were protected from ECM death. Knock-out mice died of ECM-independent causes 
in the later part of the infection (Figure 5.1). This shows that absence of IRF3 confers 
ECM protection in infected mice.     
 
Figure 5.1 Survival of WT (n=8) and IRF3KO (n=16) mice infected with 
PbAluc. The shaded area represented days when WT mice displayed neurological 
symptoms. #p<0.05; log-rank test. Result is representative of two experiments.  
 
Development of ECM is associated with focal brain damage and a compromised 
integrity of BBB [148, 320]. Presence of haemorrhage spots was observed in both 
groups of infected mice (Figure 5.2). Assessment of BBB integrity using Evans Blue 
extravasation assay revealed that ECM-resistant IRF3KO mice displayed 
significantly less vascular leakage as compared to ECM-susceptible WT mice (Figure 
5.2C). Figure 5.2B represents brains stained with Evans Blue from naïve WT, 
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infected WT, naïve IRF3KO and infected IRF3KO. Taken together, the data suggests 
that absence of IRF3 prevented extensive haemorrhagic damage and vascular leakage 
to the brain. 
 
Figure 5.2  Assessment of integrity of BBB in WT and IRF3KO mice. (A) Brain 
H&E histopathology of naïve WT, PbAluc-infected WT, naïve IRF3KO and PbAluc-
infected IRF3KO on 7 dpi. (B) Quantification and (C) qualitative brain capillary 
permeability assessed after i.v. injection of Evans Blue dye per gram of brain weight 
in naïve WT (n=5), PbAluc-infected WT (n=5), naïve IRF3KO (n=5) and PbAluc-
infected IRF3KO (n=6) mice on 7dpi. Data expressed as mean ± SD and 
representative of a single experiment. **p<0.01, Mann-Whitney test. 
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In order to examine the effect of haploinsufficiency of IRF3 allele, whereby only a 
single functional copy of the IRF3 was present, in ECM development, we crossed 
WT and IRF3KO mice to generate a F1 generation (IRF3 F1) and evaluate the ECM 
outcome. 100% of WT and IRF3 F1 mice succumbed to ECM on 8-12 dpi (Figure 
5.3). This clearly demonstrated that ECM protection requires complete absence of 
functional IRF3 and a single functional IRF3 allele is able to induce an immune 
response that leads to ECM development.   
 
Figure 5.3 Survival of WT (n=15) and IRF3 F1 (n=10) mice infected with 
PbAluc. The shaded area represents the days that WT mice displayed neurological 
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5.2.2 ECM protection is not due to changes in peripheral parasitemia, parasite or 
leukocytes sequestration in the brain  
To account for the protection conferred in IRF3KO mice, we examined several 
aspects of the infection. Peripheral parasitemia of infected IRF3KO mice did not 
deviate from that of WT mice (Figure 5.4). No significant difference in parasite 
sequestration was observed in the whole body and head of WT and IRF3KO mice 
throughout the infection (Figure 5.5A and 5.5B). Similarly, in isolated organs (Figure 
5.5C-F), especially in the brain (Figure 5.5C), similar level of parasite sequestration 
was displayed in both groups of mice on 7dpi. Next, sequestered leukocytes in the 
brain were also isolated on 7dpi when WT mice started displaying late ECM signs. 
Infection led to general increase in all populations (total leukocytes, CD4+ T cells, 
CD8+ T cells and Pb1+CD8+ T cells). No significant difference in leukocytes 
number was observed in the brain of infected WT and IRF3KO mice (Figure 5.6). 
This suggests that ECM protection in IRF3KO mice is not due to variation in parasite 
growth in the blood or parasite or leukocytes sequestration in the brain. 
 
Figure 5.4 Parasitemia (%) of WT (n=6) and IRF3KO (n=10) mice infected with 
PbAluc. Data are expressed as mean ± SD and representative of two experiments.   
 




Figure 5.5 Parasite sequestrations in WT and IRF3KO mice quantified with 
bioluminescence imaging. In vivo bioluminescence imaging of parasite biomass in the 
(A) whole body and (B) head of WT and IRF3KO mice infected with PbAluc. (C-F) 
Ex vivo quantification by bioluminescence imaging of parasite iRBC in the organs of 
PbAluc-infected WT (n=4) and IRF3KO (n=5) mice on 7dpi. Data are log 
transformed and expressed as mean ± SD and represented a single experiment.   
 




Figure 5.6 BSL in WT and IRF3KO mice. Analysis of total leukocytes, CD4+ T 
cells, CD8+ T cells and Pb1-specific CD8+ T cells sequestered in the brain of naïve 
WT (n=5), PbAluc-infected WT (n=12), naïve IRF3KO (n=6) and PbAluc-infected 
IRF3KO (n=9) mice on 7dpi. Data are expressed as mean ± SD and representative of 
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5.2.3 Absence of IRF3 does not impair activation and function of T cells  
Since there is no lack of leukocyte sequestration in the brain, we wondered if 
protection could be due to a defect in effector CD8+ T cells. When we look into the 
activation status on 4dpi when priming occurs, CD8+ T cells were normally activated 
as observed by the normal expression of CD11a and CD69. No significant difference 
in the number of activated CD8+ T cells was observed between infected IRF3KO and 
WT mice (Figure 5.7), indicating no defect in activation of CD8+ T cells in the spleen 
during priming.  
 
Figure 5.7 T cell activation status in the spleen of WT and IRF3KO mice. 
Activated CD8+ T cells in the spleen of naïve WT (n=5), PbAluc-infected WT (n=8), 
naïve IRF3KO (n=5) and PbAluc-infected IRF3KO (n=6) mice on 4dpi. Activated 
CD8+ T cells were gated on CD11a
high 
and CD69+ population. Data are expressed as 
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Although we have shown that the T cells in infected IRF3KO mice are activated on 4 
dpi, we cannot eliminate the possibility that CD8+ T cells might be gradually 
inhibited upon activation [334]. Studies in cancer immunology have repeatedly 
highlighted the importance of T cells exhaustion mediated through the programmed 
death (PD-1) pathway [335-338]. We stained for exhaustion marker, PD-1, on CD8+ 
T cells on 7dpi. A similar trend was observed in the number of PD-1 expressing 
CD8+ T cells between infected WT and IRF3KO (Figure 5.8), suggesting that the 
effector CD8+ T cells in the IRF3KO mice are as normal as those in the WT mice.  
 
Figure 5.8 PD-1 expression on CD8+ T cells in the spleen of naïve WT (n=5), 
PbAluc-infected WT (n=5), naïve IRF3KO (n=5) and PbAluc-infected IRF3KO (n=5) 
mice on 4dpi. Data are expressed as mean ± SD and representative of a single 
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Next, we study the cytotoxic T lymphocyte function of effector CD8+ T cells that are 
responsible for inducing damage in the BBB [136, 153]. Using the in vivo 
cytotoxicity assay, we confirmed that the CD8+ T cells from IRF3KO mice were able 
to perform its cytotoxic function as well as those from the WT mice (Figure 5.9A). 
Since ECM induction is dependent on GrB released by cytotoxic T cells recruited to 
the brain [147], we further analysed this population in our mice on 7dpi. Infection led 
to increase in the numbers of total and Pb1-specific GrB-producing CD8+ T cells in 
both WT and IRF3KO mice. No significant difference in numbers was observed 
between infected WT and IRF3KO mice (Figure 5.9B and 5.8C). These indicated that 
the effector CD8+ T cells in infected IRF3KO mice are activated, functional and 
possess cytotoxic capacity.   
 
Figure 5.9 Cytotoxic function of CD8+ T cells in WT and IRF3KO mice 
assessed through in vivo cytotoxic assay and intracellular staining of GrB. (A) 
Percentage of Pb1-sepcific killing in infected WT (n=3) and IRF3KO (n=7) on 7dpi. 
Equal number of CFSE
hi
 unpulsed naïve splenocytes and CFSE
lo
 Pb1-pulsed naïve 
splenocytes were transferred into infected mice on 6dpi. Mice were sacrificed 20h 
later to obtained CFSE-labelled splenocytes for analysis. Result is representative of a 
single experiment. (B) Intracellular staining of GrB in CD8+ T cell sequestered in the 
brain of naïve WT (n=6), PbAluc-infected WT (n=6), naïve IRF3KO (n=3) and 
PbAluc-infected IRF3KO (n=8) mice on 7dpi. Isolated leukocytes were incubated 
with Brefeldin A without any stimulant for 2h. Result for intracellular staining is 
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representative of three independent experiments. Data are expressed as mean ± SD. 
*p<0.05, Unpaired Student t-test.  
 
5.2.4 Defective antigen cross-presentation by brain microvessels confers ECM 
resistance in IRF3KO mice 
Effector CD8+ T cells migrated to the brain recognizes target cells expressing 
parasite antigens to induce its cytotoxic function through the release of cytolytic 
molecules such as GrB and perforin. Recent findings by Howland et al., established 
that antigen presentation by brain microvessels is the key that determines ECM 
outcome in ECM-resistant and –susceptible mice, both of which contained cytotoxic 
CD8+ T cells in the brain [136]. Result from brain microvessels cross-presentation 
assay showed that Pb1 antigen cross-presentation in infected-IRF3KO mice was 
significantly lower than in infected-WT mice (Figure 5.10). This explained why 
despite presence of cytotoxic CD8+ T cells, IRF3KO mice were still protected from 
ECM.  
 
Figure 5.10 Brain microvessels cross-presentation of naïve WT (n=5), PbAluc-
infected WT (n=6), naïve IRF3KO (n=5) and PbAluc-infected IRF3KO (n=9) mice 
on 8dpi.  Data are log transformed and expressed as mean ± SD. **p<0.01, 
***p<0.001, Unpaired Student t-test. Result is representative of two experiments. 
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To further dissect how absence of IRF3 affects antigen cross-presentation by brain 
microvessels during infection, we assessed the various aspects regulating antigen 
presentation such as MHC class I (MHC-I) expression, antigen uptake and processing. 
In the first set of experiment, we isolated brain microvessels and pulsed them with 
irrelevant chicken ovalbumin (OVA) which will be loaded on unoccupied MHC-I, as 
well as displace endogenous Pb1. Results showed no significant difference in number 
of activated OVA-specific hybridoma T cells, as represented by blue spots, between 
infected WT and IRF3KO suggesting similar expression of MHC-I in both groups 
(Figure 5.11A). Next, antigen uptake and processing was examined by culturing brain 
endothelial cells obtained from naïve WT and IRF3KO mice followed by exposure to 
same amount of schizont products and IFN-γ, which promotes antigen presentation 
(Figure 5.11B). Similarly, no difference in number of activated Pb1-specifc 
hybridoma was observed between both groups, indicating that under the same 
conditions, brain endothelial cells in IRF3KO mice is able to cross-present as 
effective as WT mice.  
 
Figure 5.11 Defective cross-presentation is independent of endogenous factors. 
(A) Cross-presentation of OVA peptide by brain microvessels of naïve WT (n=5), 
PbAluc-infected WT (n=5), naïve IRF3KO (n=3) and PbAluc-infected IRF3KO (n=4) 
mice on 8dpi. Brain microvessels isolated were pulsed with OVA and then incubated 
with OT-1 reporter cells to assess MHC-I expression. (B) Antigen cross-presentation 
by brain microvessels cultured from naïve WT (n=6) and IRF3KO (n=7) mice. Upon 
confluent culture, brain microvessels were treated with 10ng/ml IFN-γ and incubated 
with same amount of schizont products. Data are log transformed and expressed as 
mean ± SD. Results are representative of a single experiment. **p<0.01, ***p<0.001, 
Unpaired Student t-test.   
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5.2.5 Suboptimal IFN-γ production leads to defective antigen cross-presentation 
From results above, we concluded that defect in antigen cross-presentation is 
independent of endogenous factors and more likely due to external environmental 
factors. External factors such as availability of parasite products to be taken up by 
endothelial cells from brain microvessels and level of IFN-γ can regulate antigen 
presentation [150]. Previous results from ex-vivo imaging excluded the possibility of 
insufficient parasite products in the brain since no difference in parasite sequestration 
was observed (Figure 4.5). Therefore, we proceeded to measure IFN-γ in the brain. 
Using real-time PCR, we found significantly lower mRNA expression of IFN-γ in the 
brain of infected IRF3KO as compared to WT mice (Figure 5.12A). Similarly, lower 
concentration of IFN-γ was also found in the serum of infected IRF3KO mice (Figure 
5.12B). This suggested that lack of IFN-γ in infected IRF3KO mice is responsible for 
defect in antigen presentation by brain microvessels. In addition, this result also 
explain why induction of cultured brain microvessels from naïve WT and IRF3KO 
mice with the same amount of IFN-γ led to similar level of antigen presentation by 
both groups of mice.  
 
Figure 5.12 Level of IFN-γ in infected WT and IRF3KO mice on 7dpi. (A) 
Expression level of IFN-γ in the brain of WT (n=3) and IRF3KO (n=3) mice. Log2 
transformed fold changes in mRNA level (infected/naïve) were plotted. (B) 
Concentration of IFN-γ in the serum of naïve WT (n=3), PbAluc-infected WT (n=5), 
naïve IRF3KO (n=3) and PbAluc-infected IRF3KO (n=10) mice. Data are expressed 
as mean ± SD and representative of a single experiment. *p<0.05, ***p<0.001, 
Unpaired Student t-test.  
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To verify that reduced IFN-γ is mediating defective antigen presentation in infected 
IRF3KO mice, we repeated the culture of brain microvessels from naïve WT and 
IRF3KO mice but subjected them to different concentrations of IFN-γ. Antigen 
presentation by both the WT and IRF3KO mice increased in a dose-dependent 
manner and plateaued off at 1.0ng/ml (Figure 5.13). This shows that IFN-γ is indeed 
essential for antigen presentation and it correlates in a dose-dependent manner. More 
importantly, it supports our hypothesis that ECM protection in IRF3KO mice is due 
to insufficient production of IFN-γ to induce optimal antigen cross-presentation by 
brain microvessels.     
 
Figure 5.13 Dose response of antigen cross-presentation by brain microvessels 
cultured from naïve (A) WT and (B) IRF3KO mice under different concentration of 
IFN-γ (ng/ml) stimulation. Data (blue spots) are log transformed and expressed as 
mean ± SD and representative of a single experiment. 
 
In order to determine if the source of insufficient IFN-γ is produced by hematopoietic 
cells or non-hematopoietic cells, bone marrow reconstitution was performed. Bone 
marrow chimeras were generated by reconstituting irradiated WT or IRF3KO mice 
with bone marrow cells from WT mice. Serum collected from both groups of infected 
chimeras showed no significant difference in the concentration of IFN-γ (Figure 
5.14A). When chimeras were assessed for antigen cross-presentation, reconstituted 
IRF3KO mice did not display reduced antigen presentation as compared to 
reconstituted WT mice on 6dpi when infected reconstituted WT mice displayed 
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neurological signs (Figure 5.14B). When monitored for ECM survival, both WT and 
IRF3KO chimeras succumbed and died of ECM on 7 and 8 dpi (Figure 5.14C). This 
demonstrated that presence of IRF3 in hematopoietic cells is able to restore IFN-γ 
level in the serum, antigen presentation by brain endothelial cells, as well as, reversed 
ECM protection previously observed in IRF3KO mice.  
 
Figure 5.14 Effect of WT hematopoietic cells on serum IFN-γ level, antigen 
presentation and ECM survival in IRF3KO chimera. (A) Level of IFN-γ in the serum 
of reconstituted WT (n=9) and IRF3KO (n=11) on 7dpi. Data are expressed as mean 
± SD. (B) Brain microvessels cross-presentation of naïve WT (n=8), PbAluc-infected 
reconstituted WT (n=9), naïve IRF3KO (n=6) and PbAluc-infected reconstituted 
IRF3KO (n=11) mice on 6dpi. Data are log transformed and expressed as mean ± SD. 
**p<0.01, ***p<0.001, Unpaired Student t-test. (C) Survival of reconstituted WT 
(n=4) and IRF3KO (n=9) mice infected with PbAluc. The shaded area represented 
days when reconstituted WT and IRF3KO mice displayed neurological symptoms. 
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Bone marrow reconstitution identified the hematopoietic cells in IRF3KO mice as 
those responsible for the reduced IFN-γ production in our infection model. Previous 
studies demonstrated that NK cells are the largest IFN-γ-secreting population during 
early stage of infection [121, 142], and subsequently CD4+ and CD8+ T cells become 
dominant over the course of infection, [121]. Therefore, we performed intracellular 
staining at two different time points; 4 dpi to stain for NK cells and 7dpi to stain for 
CD4+ and CD8+ T cells. On 4dpi, we observed similar number of splenic IFN-γ-
producing NK cells between infected WT and IRF3KO (Figure 5.15A). Similarly, no 
significant difference in number of number of IFN-γ-producing CD4+ T cells was 
found between the two groups on 7 dpi (Figure 5.15B). However, when we assessed 
the numbers of IFN-γ-producing CD8+ T cells, infected IRF3KO has significantly 
less cells than WT mice (Figure 5.15C), suggesting that the absence of IRF3 resulted 
in a decrease in number of IFN-γ-producing CD8+ T cells.  
 
Figure 5.15 Analysis of IFN-γ-producing cells in the spleen of naïve and infected 
WT and IRF3KO mice. (A) Splenic NK cells expressing IFN-γ in naïve WT (n=5), 
PbAluc-infected WT (n=5), naïve IRF3KO (n=4) and PbAluc-infected IRF3KO (n=5) 
mice on 4dpi. Result is representative of a single experiment. IFN-γ producing (A) 
CD4+ and (B) CD8+ T cells in the spleen of naïve WT (n=4), PbAluc-infected WT 
(n=8), naïve IRF3KO (n=3) and PbAluc-infected IRF3KO (n=9) mice on 7dpi. 
Results are representative of three independent experiments. Data are expressed as 
mean ± SD. *p<0.05, Unpaired Student t-test. 
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5.2.6 Absence of IRF3 abrogates IFN-β expression  
Complete IFN-γ response has been reported to be dependent on an intact IFN-I 
signalling [247] [339]. Therefore, we investigated the upstream production of both 
cytokines in the family of IFN-I during infection. Serum level of IFN-β and IFN-ɑ 
was undetectable by ELISA on 4, 7dpi. Since the effect of IRF3 deficiency is only 
observed at the level of antigen presentation in the brain, we assessed the mRNA 
expression of both interferons in the brain on 7dpi. Significantly lower mRNA 
expression of IFN-β was observed in the brain of IRF3KO as compared to WT 
(Figure 5.16A). Of note, no difference in IFN-ɑ expression was observed between the 
two groups (Figure 5.16B). This result supports our hypothesis that reduced IFN-γ 
production is associated to defect in IFN-I signalling, and specifically in this case, 
IFN-β expression.       
 
 
Figure 5.16 Expression of (A) IFN-β and (B) IFN-ɑ in the brain of WT (n=6) and 
IRF3KO (n=9) on 7dpi. Log2 transformed fold change in mRNA level 
(infected/naïve) were plotted. Data are expressed as mean ± SD and representative of 
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5.2.8 Mice deficient of both IRF3 and IRF7 is partially protected from ECM 
Since IRF3 deficiency confers ECM protection whereas IRF7 deficiency did not alter 
ECM susceptibility, we wondered how absence of both transcription factors could 
alter the outcome of ECM. Using mice deficient of both IRF3 and IRF7 (IRF3.IRF7 
DKO), we assessed survival and neurological signs upon infection with PbAluc. 
While 100% WT mice succumbed within the ECM window, approximately 30% 
IRF3.IRF7 DKO mice died in the same period of time (Figure 5.17A). All DKO mice 
that died within the ECM window displayed signs of ECM (Figure 5.17B). Our data 
suggested that in absence of both IRF partially protected mice from ECM death. 
 
Figure 5.17 (A) Survival and (B) cumulative ECM incidence of WT (n=14) and 
IRF3.IRF7 DKO (n=15) mice infected with PbAluc. The shaded area represented 
days when reconstituted WT and IRF3KO mice displayed neurological symptoms. 
Results are combined data of two independent experiments. For ECM incidence, 















In this study, we showed that IRF3 is essential to drive the development of ECM 
pathology. In the absence of IRF3, marked reduction of IFN-β and therefore IFN-γ in 
the brain led to defect in antigen presentation by brain microvessels, which scales 
down damage in the BBB, even in the presence of functional and cytotoxic effector 
CD8+ T cells.      
 
In the previous chapter, IRF7 is redundant in the development of ECM (Figure 4.2) 
whereas in this chapter, we demonstrated that IRF3 is crucial for ECM progression 
(Figure 5.1). Further analysis of mRNA expression in brain of infected mice revealed 
that expression of IFN-β, but not IFN-ɑ, is defective in IRF3KO mice (Figure 5.16). 
Since IFN-β and IFN-ɑ production relies on the activity of IRF3 and IRF7 
respectively, and expression of IRF7 requires IFN-β signalling, it is clear that IRF3 is 
the key to initiate IFN-I signalling and production. Despite that, basal level of IFN-I 
is present within the cells at naïve state [253]. Therefore, IRF3KO mice did not have 
total ablation of IFN-I signalling; rather, IRF7 is able to participate in the positive 
feedback loop to produce IFN-ɑ, which explains for the presence of normal IFN-ɑ 
expression in IRF3KO mice. Taken together, results from the two chapters clearly 
demonstrated that IFN-β- or IRF3-dependent mechanism, but not IFN-ɑ or IRF7, is 
crucial for ECM development.        
 
In our study, absence of IRF3 conferred ECM protection due to deficiency in antigen 
presentation by brain microvessels (Figure 5.10) as the result of inadequate IFN-γ 
production. Effects of IFN-γ on antigen presentation have been well established. IFN-
γ can upregulate MHC class I expression, antigen processing and presentation [340-
342]. Recent publication by Howland et al., further proved that in the context of ECM, 
IFN-γ is an important cytokine for optimal antigen cross-presentation by brain 
microvessels, specifically the endothelial cells [150]. While seeking to identify the 
 Chapter 5 Interferon Regulatory Factor 3 
111 
 
mechanism behind this defect in antigen presentation, we revealed that it is not 
mediated through expression of MHC class I (Figure 5.11A). It remains to be 
identified exactly how each cytokine contribute to optimal antigen presentation by 
brain microvessels during infection.   
 
Intracellular staining of leukocytes identified marked reduction in number of IFN-γ-
producing CD8+ T cells in the spleen of infected IRF3KO mice (Figure 5.15C) which 
possibly accounts for the decrease in level of IFN-γ in the serum (Figure 5.12B). 
Previously, Ball et al., has identified IFN-I signalling in CD8+ T cells as a vital 
component in ECM pathogenesis. Absence of IFN-I signalling impairs CD8+ T cells 
accumulation, and more importantly, its response to antigen presentation in the brain 
tissue [119]. However, their results showed normal expression of splenic IFN-γ-
producing CD8+ T cells in IFNAR-KO mice on 5dpi whereas we observed marked 
reduction in number of IFN-γ producing CD8+ T cells in the spleen of IRF3KO mice 
on 7dpi. Such discrepancy could be attributed to the difference in time points being 
sampled. Besides, in the study they also revealed significant reduction in brain-
sequestered CD8+ T cells in IFNAR-KO mice [119] which we did not observed in 
IRF3KO mice (Figure 5.6C). Targeted mutation of IFNAR in the mice provokes total 
ablation of IFN-I signalling. On the other hand, disruption of the transcription 
initiation site of IRF3 in the IRF3KO mice merely translate into inability to produce 
IFN-β, with normal IFN-ɑ expression as depicted in Figure 5.16B. Since absence of 
IFN-β in IRF3KO mice did not alter CD8+ sequestration in the brain whereas absence 
of both IFN-ɑ and IFN-β signalling significantly decreased the numbers, we 
postulated that IFN-ɑ signalling might governs CD8+ T cells accumulation in the 
brain. This data corroborates with result from previous chapter whereby we 
demonstrated that absence of IRF7, which has a defect in IFN-ɑ production (Figure 
4.10), displayed marked reduction in CD8+ T cells sequestered in the brain (Figure 
4.4C).  
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Finally, using mice deficient for both IRF3 and IRF7, we demonstrated that combined 
deficiency in both IRF conferred protection to ECM (Figure 5.17A). This data 
coincided with previous study by Sharma and colleagues who showed that IRF3.IRF7 
DKO mice displayed ECM protection upon PbA infection [109]. However, in our 
study, some DKO mice still displayed neurological signs and succumbed to ECM 
death (Figure 5.17B).  Differences in genetic deletion or parasite clone used are likely 
to account for the difference in protection.   
 
To sum it up, results from the two chapters concluded that IFN-β is the main cytokine 
of the IFN-I family to promote ECM development. However, IRF7 and IFN-ɑ still 
play a role in PbAluc infection by controlling peripheral parasitemia. Altogether, it 
seems to suggest that IFN-β plays a pro-inflammatory role whereas IFN-ɑ promotes 
an anti-inflammatory milieu during infection.    
 



























6.1 Overall discussion 
In this project, we explore the specific role of three different IRFs in the induction of 
ECM. We concluded that two of the three IRFs, specifically IRF1 and IRF3, are 
crucial in driving ECM development. However, further study revealed that each IRF 
uniquely participate in ECM pathogenesis. The following table summarize on how 
each transcription factors affect the various important events in ECM:    
Table 6.1 Effects of different IRF deficiency on PbAluc infection.  
 IRF1KO IRF7KO IRF3KO 
ECM  Resistant Susceptible Resistant 
ECM Signs Yes Yes No 
Brain damage Less ND Less 




Lower ND ND 
Leukocyte 
Sequestration 






ND ND Less 





and CD8+ T cells 
More IFN-γ 





(ND= No difference; NA = Not applicable) 
Deficiency in IRF1 and IRF3 protected mice from ECM death. ECM protection in 
IRF1KO mice rely on defective T cells response, whereas impaired antigen 
presentation by brain endothelial cells accounts for the protection in IRF3KO mice. 
Despite protection from ECM death, neurological signs were observed in IRF1KO 
but not in IRF3KO mice, suggesting that absence of IRF3 totally prevents 
neurological manifestation, which represents a less damaged BBB. Taken into the 
account the mechanism behind ECM protection in each deficient mouse, we proposed 
that defect in antigen presentation is more effective in preventing BBB damage than 
marked reduction in brain-sequestered T cells number in the presence of normal 
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antigen presentation. This is because even in presence of significantly reduced 
number of T cells, the extent of damage in the brain is still sufficient to cause 
neurological manifestation. Based on this, we proposed that antigen presentation 
regulated by IRF3 is a crucial event in ECM pathogenesis. This corroborates with 
previous study by Howland et al., who demonstrated that antigen presentation by 
brain endothelial cells determines ECM susceptibility. In this study, she showed that 
cytolytically active Pb1-specific CD8+ T cells are present in the brain of NCM and 
ECM mice and only brain vessels of ECM mice are capable of cross-presenting [136]. 
Therefore, out of the three transcription factor studied in this project, IRF3 is the only 
factor that totally prevents ECM development.  
 
Antigen cross-presentation by brain endothelial cells is associated with parasite 
accumulation in the brain [136]. Yet antigen presentation in the brain of IRF1KO 
mice was unaffected even though significant decrease in parasite accumulation was 
observed. This suggests that the amount of parasite accumulation, though markedly 
reduced in IRF1KO mice, is still sufficient for optimal antigen presentation by brain 
endothelial cells. Besides parasite accumulation, it was recently established that IFN-
γ is required for cross-presentation by brain microvessels [150]. When we assessed 
this, both IRF1 and IRF3KO mice displayed significant decrease in IFN-γ during 
infection. This cannot account for the difference in antigen presentation observed 
between both groups of mice. Therefore, another factor exclusively regulated by IRF3 
must be involved in mediating antigen presentation. Besides IFN-γ, the brain of 
infected IRF3KO mice also displayed marked reduction in IFN-β, which was shown 
to also regulate antigen presentation [343]. Since IRF1KO mice did not display 
reduced expression of IFN-β (data not shown), we speculated that IFN-β might 
directly mediate antigen presentation during infection. It is possible that in infected 
IRF1KO mice, reduced level of IFN- γ, coupled with the presence of normal level of 
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IFN-β, enables optimal antigen presentation. Effect of IFN-β on antigen presentation 
in PbAluc infection will be further investigated to confirm this hypothesis.      
 
Besides participating in antigen presentation, IFN-γ is also crucial for the control of 
peripheral parasitemia in various model of malaria infection [314]. In our results, 
though both IRF1KO and IRF3KO displayed significant decrease in level of IFN-γ, 
only parasitemia in IRF1KO mice was affected. This is possibly due to difference in 
the source of IFN-γ. Marked decrease in number of IFN-γ secreting CD4+ and CD8+ 
T cells were observed in IRF1KO mice. On the other hand, only IFN-γ producing 
CD8+ T cells were significantly decreased in IRF3KO mice. This seems to imply that 
both IFN-γ-producing T cell populations are essential for the control of parasitemia to 
occur. However, our results in chapter 4 suggests otherwise. Absence of IRF7, though 
not crucial for ECM development, significantly increased the number of IFN-γ 
producing CD4+ T cells thus enabling control of peripheral parasitemia. Taken 
together, it is apparent that CD4+ T cell is the dominant source of IFN-γ responsible 
for the control of parasite in the circulation. This conclusion corroborates with 
previous studies demonstrating that CD4+ T cells sequestered in the brain is the 
greatest source of IFN-γ [121, 227].       
 
In this project, we established that loss of either functional IRF1 or IRF3 confers 
ECM protection in our mouse model. In human, loss or defect in functional IRF1 due 
to genetics or epigenetic alterations has been reported and such mutation can alter 
susceptibility to cancer. For example, approximately 20% of patients suffering from 
myelodysplatic syndrome (MDS) or overt leukaemia developed from MDS had a loss 
of functional IRF1 mRNA expression [344]. On the other hand, while loss of 
functional IRF3 due to genetic mutation in human has not currently been reported, 
infection with Kaposi’s sarcoma-associated herpes virus can inhibit IRF3 
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transcriptional activity [345]. Hence, it remains important to understand exactly the 
impact of such genetic mutation on disease outcome. 
 
Our results illustrate the importance of IFN-I in ECM development. IFN-ɑ is 
redundant whereas IFN-β is essential for ECM progression. Through the study of 
these three knock-out mice, we also confirmed that antigen presentation is the most 
influential factor that determines ECM susceptibility. In the presence of reduced 
malaria-specific CD8+ T cells in the brain, limited damage can still occur in the BBB 
as long as antigen presentation is not defective. Our data revealed a degree of ECM 
susceptibility in the three different knock-out mice. IRF3KO mice displayed complete 
protection from ECM; IRF1KO mice were protected but manifested neurological 
signs; IRF7KO mice were completely susceptible to ECM death. Both IRF1KO and 
IRF3KO mice that were protected from ECM death had similarly reduced level of 
serum IFN-γ and number of secreting T cell, suggesting that a weaker IFN-γ response 
protected mice from ECM death. On the other hand, IFN-γ, especially those produced 
CD4+ T cells, controls parasitemia. This demonstrated that the immune response 
needs to strike a balance between a need to control peripheral parasitemia and 
preventing the induction of ECM.  
 
6.2 Future Work 
Through the use of recombinant interferon treatment, Vigario et al., and Morrell et al., 
demonstrated that both IFN-ɑ [245] and IFN-β [112] are essential for ECM 
development respectively. However, in our study, we only observed that IFN-β, 
regulated by IRF3, affects induction of ECM. Such discrepancies could be due to the 
amount of systemic IFN-I during infection. To further validate the role of each IFN-I 
in ECM development, recombinant IFN-ɑ or IFN-β should be administered into 
IRF7KO or IRF3KO mice respectively. If the phenotype is solely regulated by each 
IFN-I, all parameters altered in the knock-out mice should be restored. 




IRF8, together with IRF1, promotes Th1-dominated immune response. IRF8 is 
uniquely expressed in immune cells and mutation in both human and mice affected 
the myeloid compartment, in particular the DC. Brain of ECM-susceptible mice 
expressed upregulation of this transcription factor [126] and functionally defective 
IRF8 protected mice from ECM death [113]. Further mechanistic study is required to 
determine how this regulatory factor mediates ECM development.     
 
Recently, IFN-III has been classified as a novel class of anti-viral cytokines. It 
comprise of IFN-λ1/IL-29, IFN-λ2/IL-28A, IFN-λ3/IL-28B [346, 347]. During 
Sendai virus infection, it was revealed that IFN-λ1 is regulated by both IRF3 and 
IRF7 whereas IFN-λ2/3 is controlled by IRF7 [348]. Thus far, no study has yet to 
investigate the role of this family of cytokines in malaria infection or ECM. Since we 
demonstrated that IRF3KO mice are protected from ECM, it would be interesting to 
study the role of IFN-λ1 in driving ECM progression. On the other hand, IRF7 is 
essential for the control of parasitemia through IFN-γ-producing CD4+ T cells so it 
remains to be investigated if IFN-λ2/3 participates in anti-parasitic immunity.          
 
Current treatment recommendations for HCM mainly target the control parasite 
growth. Parenteral administration of adequate and safe dose of anti-malaria drug is 
regarded as the most appropriate clinical care [25]. To propose adjunctive treatment 
therapy, we need to elucidate progression of this neuropathology. We and others have 
proven repeatedly that IFN-γ is pivotal in the disease progression. However, 
monoclonal antibody targeting this cytokine is not recommended as IFN-γ is also 
essential for control of parasite in the circulation; therefore, we need to seek 
alternative options. Our result corroborates a previous study by Howland et al., who 
demonstrated that antigen presentation by brain microvessels, which correlates with 
parasite sequestration, is the hallmark of ECM. Parasite sequestration in HCM has 
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been widely reported. Taken together with the knowledge that human brain 
endothelial cell line is able to acquire proteins from Pf iRBC, it highly suggests that 
cross-presentation can also occur on human brain endothelial cells during HCM. 
Therefore, targeting cross-presentation by brain endothelial cells might prove 
effective for as an adjunct treatment. However, more study needs to be performed to 
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